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Acute liver failure continues to be a major medical problem. There are many underlying causes of 
acute liver failure, but drug induced liver injury is the most common. However, ischemic injury 
secondary to either liver transplantation or hypoxic hepatitis are also commonly encountered 
clinically. While the pathogenesis of some etiologies of liver failure are well known due to 
appropriate animal and cell culture models (i.e. acetaminophen toxicity), that of ischemic injury is 
not as well documented. A major reason for this is the lack of appropriate animal models available 
to recapitulate these conditions in humans. Furthermore, obtaining multiple liver biopsies to study 
these conditions at the cellular level is generally not possible owing, in part, to the invasive nature 
of obtaining the sample, but also to the fact that liver biopsies are contraindicated in acute liver 
injury patients. Thus, alternative methods which can help diagnose and study liver injury are being 
explored and refined. Among these methods are the use of circulating biomarkers, which are 
currently being extensively explored in the field of hepatology. Because biologic specimens in 
which these biomarkers are being measured can be easily obtained and are non-invasive, they offer 
a promising means by which to study liver injury, particularly for prolonged periods of time. 
Indeed, a series of blood collections can provide vital information into various injury-specific 
aspects of liver pathophysiology including mode of cell death, mitochondrial involvement, degree 
of liver injury, and presence or absence of a sterile inflammatory component to the injurious 
process. 
Here, we use a well-established set of circulating plasma biomarkers to study the pathophysiology 
of both warm and cold ischemia to better characterize the cellular events which take place during 
these conditions. Data obtained demonstrates that during both warm and cold ischemia, the 
majority of injury occurs early in the reperfusion period and that necrosis, rather than apoptosis 
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predominates. Furthermore, we identified the mitochondria as critical mediators of liver injury 
following ischemia. However, we were unable to find evidence of an inflammatory component of 
ischemic injury. Furthermore, we conclude that due to advances in surgical technique and organ 
preservation strategies, future efforts to study injury secondary to liver transplantation should focus 
on the biliary system and the formation of biliary strictures rather than ischemic injury. 
HepaRG cells are a human hepatoma cell line which is commonly used in the laboratory. Unlike 
other liver cell lines, HepaRG cells have a full complement of drug metabolizing enzymes, making 
them ideal for the study of drug induced liver injury. However, growth, maintenance, and 
differentiation of conventional HepaRG cells is a timely process. Recently, this lengthy process 
has been dramatically shortened with the advent of pre-differentiated cryopreserved HepaRG cells. 
Due to the frequency of acetaminophen toxicity, combined with the fact that liver injury is the 
most common cause of drug failure and market withdrawal, we set out to compare these two 
preparations of HepaRG cells. Using acetaminophen as a test substrate, we found both preparations 
of HepaRG to be similar in all aspects of acetaminophen metabolism. This finding will help 
advance the study of acetaminophen, as well as help identify idiosyncratic adverse drug reactions 
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1.1 ACUTE LIVER INJURY 
 
1.1.1 Introduction 
Acute liver injury (ALI) and acute liver failure (ALF) are clinical syndromes marked by severe 
hepatic injury in the absence of pre-existing liver disease. Acute liver injury can develop over a 
period of 6 months but often progresses much more rapidly (Lee, 2012). The difference between 
ALI and ALF is that with acute liver injury, liver function is maintained while in acute liver failure, 
it is not. Consequently, clinical measurements of liver function can easily be used to differentiate 
between acute liver injury and acute liver failure. In ALF patients, there is often coagulopathy, 
icterus, and altered mentation as a result of compromised liver function (Thawley, 2017; Trotter, 
2009). The most common cause of acute liver failure in the United States is acetaminophen 
toxicity. Other common causes include ischemic injury secondary to liver transplantation and 
hypoxic hepatitis. Regardless of the cause, if left untreated, ALF can be fatal. 
 
1.1.2 Clinical Symptoms of ALF 
The liver is the largest organ in the body and serves multiple functions including bile synthesis, 
host defense, protein synthesis, biotransformation/detoxification, and metabolic homeostasis. 
Therefore, patients with advanced liver failure are at risk for complications resulting from the 
inability of the liver to function, most notably coagulopathies and hepatic encephalopathy. 
Coagulopathies secondary to liver injury result from disturbances in the synthesis of pro-coagulant 
proteins, particularly Factors V and VII (Munoz et al., 2009; Northup and Caldwell, 2013). 
Because of the short half-lives of these pro-coagulants, an increase in pro-thrombin test time is 
often one of the first clinical signs of acute liver failure (Munoz et al., 2009). Hepatic 
encephalopathy results from the injured liver’s inability to convert ammonia into urea (Kodali and 
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McGuire, 2015). Under normal circumstances, gut-derived ammonia is taken up by hepatocytes 
and converted to urea. A small amount is also converted to glutamine by the enzyme glutamine 
synthetase (Aldridge et al., 2015). During acute liver failure, the ability of the liver to detoxify 
ammonia is compromised. As a consequence, ammonia levels raise within the serum and are able 
to cross the blood-brain barrier (Kodali and McGuire, 2015). Once in the brain, ammonia is 
converted to glutamine by astrocytes, which causes an osmotic pull of fluid from blood vessels 
into the extracellular space (Butterworth, 2015; Kodali and McGuire, 2015; Scott et al., 2013). At 
lower concentrations, ammonia also has direct effects on both inhibitory and excitatory neurons 
leading to altered patient mentation (Butterworth, 2015). Higher levels of ammonia can lead to 
cerebral edema, increased intracranial pressure, brain swelling, coma, and death.  
There are many biochemical assays commonly used to assess liver injury and function. The most 
common markers of injury include alanine and aspartate aminotransferase (ALT and AST, 
respectively), cytosolic enzymes which are released upon hepatocyte death. The most common 
marker of liver function is bilirubin levels. It is important to remember that markers of liver injury 
may remain normal despite significantly decreased function. Conversely, liver function may 
remain normal in the face of severe hepatic injury, provided that the number of healthy hepatocytes 
are sufficient to carry out normal function. Thus, evaluation of liver injury and function should not 
rely on a single marker. Furthermore, these enzymes often provide little information as to the 
mechanisms which are occurring at the cellular level. When this information is lacking, 
development of additional therapeutics for liver disease cannot be identified. As such, scientists 
within the hepatology field have begun to focus their efforts on identification of other markers of 
cellular injury and death which may provide additional information regarding mode and 
mechanisms of cell death during acute liver injury and failure. 
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1.1.3 Biomarkers in Hepatology 
1.1.3.1 Introduction to biomarkers 
Some of the first biomarkers of liver injury were the aminotransferases – ALT and AST in 1955 
(Karmen et al., 1955). Gamma-glutamyl transferase (GGT) was discovered and adopted into 
clinical practice in 1961 (Szczeklik et al., 1961) but since then, very few advances have been made 
in the identification of additional biomarkers of liver injury. However, in the previous decade, 
much research has been conducted to identify additional biomarkers of organ pathology. Broad 
categories of this biomarker research include mechanistic biomarkers, biomarkers of injury, 
biomarkers of inflammation, biomarkers of regeneration, and extracellular RNA based biomarkers 
specific to the organ in question (McGill, 2016). Drug induced liver injury, viral hepatitis, 
hepatocellular carcinoma, and hepatic steatosis appear to be among the most commonly studied 
conditions in the hepatology field, but applications in other fields such as transplantation, hypoxic 
hepatitis, and biliary diseases have been studied as well. Regardless, it is hypothesized that soon, 
the use of these biomarkers in the clinic will become as normal as the use of ALT, either in 
conjunction with, or instead of, currently used markers of injury (McGill, 2016). Regardless, there 
has been a tremendous amount of useful information gained from this research, particularly 
regarding their usefulness in the diagnosis, treatment, management, and prognosis of various 
causes of ALF, regardless of the etiology.  
The most commonly used method of assessing liver injury in the clinic is ALT levels. However, 
ALT is not specific to the liver as it is also found in other tissues such as skeletal muscle and 
kidney. Thus, even a moderate increase in ALT may not indicate an injurious process specific to 
the liver. Furthermore, measurement of ALT provides little information as to the cellular 
mechanism of cell death. This is important because in addition to treatment of the underlying 
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cause, an important approach to treating ALF patients would be to prevent continued hepatocyte 
injury and death. Thus, if hepatocytes are dying via necrosis, necrostatins may be used to minimize 
cell death. Similarly, if apoptosis predominates, caspase inhibitors could be used as the optimal 
treatment modality.  
Recent advances in the field of hepatology have identified a reliable set of circulating biomarkers 
which can be used to help establish both mode and mechanism of cell death following hepatic 
injury. In general, biomarkers can be classified as those of exposure, effect, or susceptibility. For 
the purpose of this dissertation, the research described subsequently focuses on biomarkers of 
effect – either the effect of a condition (ischemia-reperfusion injury) or the effect of a toxin 
(acetaminophen). These biomarkers, discussed in detail below, represent a promising and 
convenient method of assessing liver injury in humans following a variety of insults to the liver 
when invasive methods (ie: biopsy) are either unavailable or contraindicated. The greatest benefit 
to the use of these biomarkers is that they exist in the general circulation, and thus can be evaluated 
in peripheral blood.  
The bulk of this dissertation will focus on the use of the following mechanistic biomarkers to aid 
in the description of the cellular events leading up to liver injury following ischemia-reperfusion 
injury secondary to orthotopic liver transplantation (OLT) and hypoxic hepatitis (HH). 
 
1.1.3.2 Biomarkers of Liver Injury  
ALT is responsible for the transfer of an amino group from alanine to α-ketoglutarate to form 
pyruvate and glutamate and is found in the cytosol of hepatocytes. Alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) are cytosolic enzymes which catalyze the transfer of 
alanine, or aspartate, to α-ketoglutarate to form pyruvate and glutamate or oxaloacetate and 
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glutamate, respectively. Though they exist in multiple tissues such as the muscle, kidney, brain, 
and red blood cells, their highest concentration is in the liver (Steven Stockham and Michael Scott, 
2002). Upon cell death, these cytosolic enzymes are released into the sinusoids and can easily be 
measured in the blood. In fact, ALT is considered the gold standard for the measurement of liver 
injury clinically (Steven Stockham and Michael Scott, 2002). Despite the sensitivity for liver 
injury, ALT and AST have limited specificity for diagnosis of liver injury, particularly at low 
levels. In contrast, microRNA-122 (miRNA-122) is liver specific. MicroRNAs are small non-
coding RNAs thought to be formed by the cell as a means to regulate protein expression at a post-
transcriptional level. Importantly, it has been shown that miRNA-122 is a more sensitive marker 
for liver injury than ALT, becoming elevated earlier and to a greater degree than ALT (Wang et 
al., 2009a). A faster identification of injury following transplantation would allow for a more rapid 
response and treatment. MicroRNAs will be discussed in more detail below.  
 
1.1.3.3 Biomarkers of cell death modality 
There are many forms of cell death, but the most common are apoptosis and necrosis. Recently, 
research has been conducted into the use of circulating biomarkers to differentiate between these 
two forms with the need for invasive biopsy procedures. Cytokeratin-18 is one such biomarker. 
Cytokeratin-18 is a type 1 intermediate filament protein which is ubiquitous in the cytoplasm of 
cells (Omary et al., 2009). Following membrane rupture from oncotic necrosis, cytokeratin-18 is 
released in its full-length form (FK18). During apoptosis, however, activated effector caspases 
cause cleavage of cytokeratin-18 at aspartic acid #397 (Asp397) along the protein, cleaving it into 
to smaller caspase-cleaved fragment (ccK18) and creating a neo-epitope (Leers et al., 1999; Linder 
et al., 2010; Omary et al., 2009). Commercially available kits containing antibodies to full-length 
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and caspase-cleaved cytokeratin-18 (ccK18) allowing for the easy quantification of FK18 and 
ccK18. In this way, by comparing the ratio of FK18 to ccK18 it is possible to determine which 
mode of cell death is predominating at any given point in time. In fact, after subjecting mice to 45 
minutes of ischemia followed by various periods of reperfusion, up to 24hr, we found a time 
dependent increase in full length cytokeratin-18 which closely correlated with degree of liver 
necrosis, as determined histologically, suggesting the primary mode of cell death after IRI is 
necrosis (Yang et al., 2014). A study evaluating cytokeratin-18 in humans undergoing liver 
transplantation shows that there is an increase in FK18 following transplantation, suggesting that 
necrosis predominates following OLT (Ulukaya et al., 2010). However, this study compares the 
differences in living donors versus cadaveric donors, the livers of which undergo different 
procurement procedures, as well as surgical procedures which can affect liver viability following 
transplantation (Jassem et al., 2003; Oliveros et al., 2005). In addition, no measurement of ccK18 
is shown here, which is crucial since we have also shown a slight increase in ccK18 at 3 hours 
post-reperfusion, when no relevant amount of apoptosis is present. This is because the 
corresponding increase in FK18 is >150-fold greater (Yang et al., 2014). Thus, it is the ratio of 
FK18 to ccK18 that is necessary to make conclusions about mode of cell death.  
In addition to helping differentiate between apoptosis and necrosis, cytokeratin-18 has a number 
of other practical diagnostic and prognostic applications for a variety of liver disorders. For 
malignancies, much use of cytokeratins comes from immunohistochemical staining, which 
necessitates biopsy. Therefore, an in-depth discussion of cytokeratins for this purpose would be 
beyond the scope of this dissertation. Nevertheless, malformations in keratin organization have 
been shown to predispose individuals to certain conditions such as copper storage disease and non-
alcoholic steatohepatitis (Ku et al., 2007; Strnad et al., 2012; Zatloukal et al., 2007). The thought 
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is that these malformed keratin structures contribute to hepatocyte ballooning in these conditions 
(Guy et al., 2012; Lackner, 2011). Furthermore, overexpression of cytokeratin variants have been 
useful in differentiating between various tumor types. For instance, HCC can be differentiated 
from cholangiocarcinoma by the overexpression of K19 relative to K18 because hepatocytes only 
contain cytokeratin-8 and -18 whereas cholangiocytes contain K8, 18, and 19 (Moll et al., 2008; 
Omary et al., 2009).  
More relevant to the field of circulating biomarkers is that elevated levels of caspase-cleaved 
cytokeratin is present in patients suffering from NASH and can help not only differentiate NASH 
from simple steatosis, but may also be correlative with the degree of severity (Alkhouri et al., 
2011; Molnar et al., 2011; Musso et al., 2011; Wieckowska et al., 2006). This is also true for 
chronic HBV and fibrotic injury associated with HCV (Bantel et al., 2004; Papatheodoridis et al., 
2008). In fact, circulating cytokeratins are the only non-invasive marker currently being used for 
the diagnosis of NASH. A recent study demonstrated that cytokeratin-18 fragments were able to 
predict the presence of NASH in patients with a sensitivity of 0.78, specificity of 0.87, and area 
under ROC of 0.82 (Musso et al., 2011). Similarly, in cases of acute liver failure, an increase in 
caspase-cleaved cytokeratin-18 was also associated with favorable prognosis and elevated full 
length cytokeratin-18 indicated more significant liver injury and a poor outcome (Bechmann et al., 
2010; Volkmann et al., 2008). However, there is conflicting data suggesting that outcome is more 
dependent on etiology than on M65 levels; in one study of APAP toxicity, evaluation of keratin 
fragmentation did not appear to offer additional benefit in predicting outcome relative to the 
currently used ALF criteria (Craig et al., 2011). On the other hand, in a study of patients who 
presented to the ER for APAP overdose, elevated full length cytokeratin-18 levels were shown to 
be highly predictive of which patients would go on to develop liver injury (Antoine et al., 2013). 
9 
 
While these numbers may not be ideal, they are much better than the use of ALT levels at the time 
of presentation for the prediction of development of liver injury. Finally, keratin-18  may be able 
to predict which patients will respond to anti-HCV therapy (Volkmann et al., 2008). Further 
research into cytokeratins will provide more information into their use as both predictive as well 
as prognostic biomarkers and will make them a more valuable clinical resource, particular in 
conjunction with other markers of injury. 
HMGB-1 is a nuclear protein which sits in the minor groove of DNA and acts as a transcription 
factor for a variety of proteins. HMGB-1 exists in two forms, a hypo-acetylated (HMGB-1) form 
and a hyper-acetylated form (acHMGB-1) (Antoine et al., 2009; van Golen et al., 2012). In its 
hyper-acetylated form, acHMGB-1 is actively secreted by macrophages and represents a pro-
inflammatory biomarker (Antoine et al., 2009; Bonaldi et al., 2003). However, during necrosis, 
hypoacetylated HMGB-1 is passively released into sinusoids and acts on macrophages through 
toll-like receptors to produce cytokines (Tsung et al., 2005; Yang et al., 2010). Studies conducted 
by our laboratory, and others, have shown that increased levels of total HMGB-1 correlate with 
degree of necrosis, particularly during earlier time points (Tsung et al., 2005; Yang et al., 2014). 
Oxidation status of non-acetylated HMGB1 can also differentiate between necrosis and apoptosis 
and whether or not an immune response may be generated. Isoforms of HMGB1 which contain 
reduced residues are generally associated with necrosis and facilitate chemotaxis and cytokine release 
from innate immune cells. The opposite is true of isoforms of HMGB1 which contain fully oxidized 
residues and are associated with apoptosis and the lack of an innate immune response (Tang et al., 
2010, 2012) Thus, much like cleaved and full-length cytokeratin, the ratio of oxidized to reduced 
isoforms of HGMB1 can be used to differentiate between necrosis and apoptosis. Furthermore, 
correlations between HMGB1 and outcome have been identified following acetaminophen toxicity in 
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humans (Antoine et al., 2013). Finally, caspase activity and cleaved caspase protein (particularly 
caspase-3) can be used as markers of apoptotic cell death, but more research needs to be conducted 
before their application in the clinical setting can be assessed (McGill et al., 2012; Woolbright et al., 
2015)  
 
1.1.3.4 Biomarkers of Mitochondrial Injury 
The premise with all mechanistic biomarkers of cellular injury and death is that they are only 
released into circulation as a result of cellular injury. For instance, mitochondrial DNA (mtDNA) 
exists within the mitochondrial matrix and injury to the mitochondria would lead to release of 
mtDNA into the cellular matrix. However, this alone would not be expected to cause an increase 
in circulating mtDNA, provided, of course, that the injury to the mitochondria was not sufficient 
to cause cellular death.  
Drug hepatotoxicity often involves mitochondrial damage and dysfunction (Pessayre et al., 2012). 
Indeed, during APAP toxicity, which is the major cause of DILI, mitochondrial injury is a critical 
feature of liver injury (Jaeschke et al., 2012a). As a result, several biomarkers of mitochondrial 
injury have been identified.  
Glutamate dehydrogenase (GDH) is an enzyme situated within the mitochondrial matrix. Using 
NAD+ as a cofactor, GDH catalyzes the conversion of glutamate to oxoglutamate – forming 
ammonia and NADH. Critically, mitochondrial injury must occur for GDH to exist in measurable 
amounts in the plasma. This is exemplified by studies comparing hepatotoxic drugs which have 
different mechanisms of action. For instance, both acetaminophen and furosemide cause 
hepatocyte injury but only APAP toxicity leads to mitochondrial injury. In studies comparing 
APAP to furosemide, measurements of GDH following acetaminophen toxicity are elevated while 
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those following furosemide toxicity are not (McGill et al., 2012). This is because if mitochondrial 
rupture does not precede necrosis, in-tact mitochondria can be removed from plasma prior to the 
measurement of GDH. Previous studies from our lab have shown definitively that mitochondria 
play a critical role in hepatocyte necrosis following acetaminophen toxicity (McGill et al., 2012) 
and data using rodent models of ischemia suggests this may be true in humans following OLT 
(Yang et al., 2014).    
In conjunction with GDH, measurement of mitochondrial DNA within the plasma can be used to 
identify mitochondrial injury. During the measurement of mtDNA, total DNA is isolated from the 
plasma, then subjected to PCR, using primers for genes encoded specifically by mitochondrial 
specific DNA, such as NADH dehydrogenase or Cytochrome C oxidase subunit 3. In studies 
detailed in this dissertation as well as those of acetaminophen metabolism, mtDNA is not only 
elevated in patients with liver injury relative to those without liver injury, but preliminary data 
from our lab suggests that elevations in GDH and mtDNA may even slightly precede elevations in 
ALT, underscoring the critical role of mitochondrial injury in cell death under these conditions. 
Although mores studies are needed to confirm this, it would seem to indicate that therapies targeted 
towards the prevention of mitochondrial injury would have a tremendous impact on the 
progression of liver injury in these conditions.  
In addition to these matrix macromolecules, Bajt and co-workers have shown that damage to the 
mitochondria also results in release of apoptosis inducing factor (AIF) and endonuclease G (Bajt 
et al., 2006). Endonuclease G then translocates to the nucleus where it begins cleaving nuclear 
DNA into fragments, ultimately leading to necrosis (Bajt et al., 2006, 2008, 2011). Therefore, 
measurements of nuclear DNA fragmentation following OLT in humans may be indicative of 
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mitochondrial involvement. Indeed, in rodent models of IRI, there is an increase in both 
biomarkers, suggesting a role of mitochondrial involvement (Yang et al., 2014).   
  
1.1.3.5 Nucleic Acid Biomarkers 
Regardless of whether cell death mode is necrosis or apoptosis, the final step in the death process 
involves DNA fragmentation. Therefore, it is not surprising that identification of methods to 
measure DNA fragmentation have been explored as a biomarker of cell death. The biggest 
drawback to the use of older tests such as gel electrophoresis and the TUNEL assay is that they 
require invasive means for acquisition. Nevertheless, when liver tissue can be obtained, these tests 
can provide valuable information regarding both the degree and mode of cell death. This is because 
the extent of DNA fragmentation correlates with the degree of cellular injury, and the pattern of 
fragmentation varies due to differences in the cellular pathways for apoptosis and necrosis. During 
apoptotic cell death, activated effector caspases (ie: caspase-3) cleave the inhibitor of caspase 
activated DNAse (iCAD) protein, allowing CAD to cleave DNA. Once activated, CAD cleaves 
DNA at regular intervals of about 180-200 bp, or multiples thereof. In contrast, during necrosis, 
DNA fragmentation is random, leading to DNA fragments of random size. The resulting 
electrophoresis pattern following apoptosis would therefore show up as a ‘ladder’ of bands as a 
result of numerous fragments of similar size but would appear as a ‘smear’ with no distinct 
identifiable band following necrosis. While gel electrophoresis can provide valuable information 
into the mode of cell death, it provides little information into the extent of injury. The opposite is 
true for the TUNEL assay, which based on the degree of staining can show extent of injury relative 
to another test compound, or contro group (Duan et al., 2016). Although this assay is not specific 
for apoptotic cell death, the pattern of staining can still provide information as to whether apoptosis 
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or necrosis predominates. This is because during apoptosis, TUNEL staining will appear as 
punctate areas in shrunken cells which have been pulled away from neighboring cells. In contrast, 
during necrosis, the TUNEL staining often encompasses large areas of tissue as a result of 
membrane rupture and spillage of DNA fragments into the surrounding area (Yang et al., 2014).  
Recently, methods have been developed which allow for the measurement of nuclear DNA 
fragmentation in plasma following liver injury. This assay is commercially available and utilizes 
the principle of the ELISA assay and uses a primary capture antibody against histones. Following 
incubation with secondary antibody, a colorimetric reaction occurs and the intensity of this color 
change can be compared between different injury groups as well as healthy volunteers. Nuclear 
DNA fragmentation has been assessed in a variety of liver conditions such as acetaminophen 
toxicity, liver transplantation, and hypoxic hepatitis (Bajt et al., 2006; McGill et al., 2012; 
Weemhoff et al., 2017). While this can provide information into the extent of injury, it does not 
provide any information into the mode of cell death. In fact, one of the biggest drawbacks to this 
assay is that if the DNA fragment is long enough, it may actually fold back onto one or more 
additional primary antibodies, thus over estimating the amount of injury.  
One of the most rapidly growing topics in the field of biomarker research is micro-RNAs, or 
miRNA. Micro-RNAs are short, non-coding RNA sequences which regulate gene expression of 
numerous proteins by inhibiting translation of mRNA (Bala et al., 2009; Cortez and Calin, 2009). 
Since they were first identified in 1993, much research has been conducted on the role of miRNAs 
in pathways such as cell death, differentiation, proliferation, and the pathogenesis of infectious 
and neoplastic diseases (Bala et al., 2009; Lee et al., 1993; Voinnet, 2005; Zamore and Haley, 
2005). Micro-RNAs are being used to not only assess extent of cell death, but also to help 
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differentiate between underlying etiology. In fact, the vast majority of biomarker research has been 
conducted in this particular field and the future of the use miRNA as a clinical tool is promising.  
The use of miRNA, particularly miRNA-122, in the field of hepatology is of benefit because this 
miRNA-122 is specific to the liver. Thus, unlike other markers of liver injury such as ALT, 
elevated miRNA can only be attributed to liver injury. The correlation between liver injury and 
increases of miRNA have been shown in numerous studies (Ward et al., 2014; Weemhoff et al., 
2017). In fact, miRNA-122 levels may be a more sensitive marker of liver injury than ALT as 
numerous studies have shown it to become elevated prior to ALT (Dear et al., 2014; Wang et al., 
2009b; Ward et al., 2014).  
While the studies detailed in this dissertation have focused only on miRNA-122, many other 
microRNAs have been studied and described in the context of liver injury. Other miRNAs such as 
miR-192 and miR-125b, are elevated in plasma or serum after acetaminophen toxicity in humans 
and in mice (Krauskopf et al., 2015; McGill and Jaeschke, 2015; Ward et al., 2014; Yang et al., 
2015). Furthermore, some studies of the liver specific miRNA-122 have not only been shown to 
be predictive of the development of liver injury in early-presenting acetaminophen overdose 
patients, but is also associated with a poor outcome (Antoine et al., 2012, 2013).  
The use of miRNAs as biomarkers is multifaceted and goes well beyond the measurement of cell 
death and prediction of injury and outcome following acetaminophen toxicity. Indeed, circulating 
miRNA profiles could be beneficial in differentiating the underlying cause of injury. In a 2014 
study, expression profiles of various liver specific miRNAs were used to help differentiate between 
APAP toxicity and hypoxic hepatitis (Ward et al., 2014). Additionally, specific changes in miRNA 
expression profiles have been associated with specific liver diseases such as non-alcoholic fatty 
liver disease, alcoholic liver disease, primary biliary cirrhosis, and hepatocellular carcinoma 
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(Dolganiuc et al., 2009; Jin et al., 2009; Ladeiro et al., 2008; Li et al., 2009; Murakami et al., 2006; 
Padgett et al., 2009). Using the knowledge gained from miRNA profiles in these types of diseases, 
research has been carried out to explore the possibility of miRNA as a therapeutic mechanism to 
counteract aberrant expression of miRNA during disease processes. In one example therapeutic 
silencing of miRNA-122 lead to a significant decrease in HCV levels in chimpanzees (Lanford et 
al., 2010). In another study, HCC progression was reversed following miRNA-26a administration 
(Kota et al., 2009). Finally, overexpression of miRNA-150 and 194 leads to decreased stellate cell 
activation, potentially playing a critical role in the therapy of liver fibrosis (Antoine et al., 2015).  
 
1.1.3.6 Other Biomarkers 
In the rapidly growing field of biomarker research, new markers of injury are constantly being 
identified and investigated. In some cases, markers of other organ systems have been investigated 
for their use as markers of liver injury. For instance, kidney injury molecule-1 can be a sensitive 
predictor of outcome following APAP overdose (Antoine et al., 2015). The relationship between 
KIM-1 and liver injury is of particular importance for determining the urgency of liver 
transplantation in these cases. 
In addition to plasma biomarkers of liver injury, several studies have identified a number of 
changes in urine composition as a method to assess liver injury (Amacher, 2002). For instance, 
urinary biomarker profiles following exposure to several hepatotoxicants were used to differentiate 










Ischemia-Reperfusion Injury (IRI) is the process by which reintroduction of oxygen to a previously 
ischemic organ leads to exacerbation of injury to that organ. IRI has been described for decades 
and observed in a number of organs, including the heart (Hausenloy and Yellon, 2013), liver 
(Jaeschke, 1991; Marubayashi et al., 1986), and kidneys (Chatauret et al., 2011). Clinically, IRI 
can occur during veno-occlusive disease, severe hypotension, or hemorrhagic shock (Eltzschig and 
Eckle, 2011). It can also be introduced iatrogenically during the Pringle Maneuver, when blood 
supply to an organ is intentionally occluded to prevent blood loss during prolonged surgical 
procedures. In the context of the liver, this can occur during lobectomy, mass removal, or 
transplantation.  
After decades of research in rodent models of IRI, much has been learned about the mechanisms 
of injury following an ischemic insult to the liver (Jaeschke, 2003). Despite these advances, little 
is known about the mechanisms of reperfusion injury in humans. Even in rodent models there is 
considerable debate about the mechanisms of injury, though recent studies by our laboratory have 
conclusively demonstrated that necrotic rather than apoptotic cell death predominates (Gujral et 
al., 2001; Yang et al., 2014). Determination of the type of cell death is important for the design of 
therapeutic agents intended to minimize injury following ischemia.  
One difficulty in characterizing the mechanisms of ischemic injury in humans, particularly over 
longer periods of time, is that multiple biopsies in human patients during liver injury is not 
possible. Thus, histologic evaluation to determine mode of cell death and neutrophil infiltration 
cannot be used. Therefore, we sought to use the specific circulating biomarkers discussed above 
to characterize mode of cell death, the role of mitochondria in cell death, and the role of 
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inflammation leading up to, and following, cell death following ischemia-reperfusion injury. 
Importantly, these same biomarkers provide useful insight into prognosis of patients suffering from 
other clinical conditions such as acetaminophen toxicity and cholestasis. 
  
1.2.2 INFLAMMATION DURING ISCHEMIA-REPERFUSION INJURY 
 
In rodent IRI, Kupffer cells and neutrophils play a significant role in the initiation and propagation 
of injury, respectively (Jaeschke and Farhood, 1991a; Jaeschke et al., 1992, 1993). Through the 
activation of Kupffer cells and the subsequent release of cytokines, neutrophils are recruited to the 
area and mediate the later phase of injury. Studies have demonstrated that antibody-mediated 
depletion of neutrophils affords substantial protection following IRI in rodents (Jaeschke et al., 
1990). In addition to pro-inflammatory, anti-inflammatory, and regenerative mediators are also 
released (Lentsch, 2012). Thus, the balance between injury and repair is dependent on the balance 
of these cytokines. Indeed, increased pro-inflammatory and decreased anti-inflammatory 
chemokines are associated with increased injury and risk of graft rejection (Camargo et al., 1997; 
Friedman et al., 2012; Tomiyama et al., 2008; Zhai et al., 2008).  
As mentioned previously, HMGB-1 can be a marker of necrosis, but can also serve as a marker of 
inflammation. A study evaluating the presence of HMGB-1 following OLT found a measurable 
amount of HMGB-1 in the early stages of reperfusion but not in the later stages, suggesting 
necrosis occurs during the early phase of injury (Ilmakunnas et al., 2008), which is in agreement 
with our rodent studies (Yang et al., 2014). This study concludes there is no correlation between 
HMGB-1 and inflammation, as measured by TNF-α and IL-6 (Ilmakunnas et al., 2008). However, 
these conclusions were based on total HMGB-1, which is released passively during necrosis, rather 
than hyper-acetylated HMGB-1, which is released actively and serves to initiate an immune 
18 
 
response. Studies from our laboratory demonstrate an increase in HMGB-1 corresponding to 
necrosis at the earlier time points, and an increase in acHMGB-1 corresponding to inflammation 
at later time points, underscoring the importance of measuring both forms of HMGB1 (Yang et 
al., 2014).  
In previous studies using the rodent model of IRI, an increase in neutrophil priming and activation 
(CD11b expression) was observed. This correlated with degree of injury at later time points 
following ischemia (Jaeschke et al., 1992, 1993) and confirmed the importance of neutrophils in 
the late stage of injury. Neutrophils are also capable of phagocytosis which can both help stop the 
inflammatory process by removing inflammatory debris, and it can also prepare the tissue for 
regeneration. In fact, neutrophil infiltration is crucial for regeneration following acetaminophen 
overdose (Williams et al., 2014). A study examining the role of neutrophils in human OLT injury 
concluded that despite early (5 minutes post-reperfusion) activation of neutrophils, there was no 
effect on graft function, suggesting neutrophil activation does not exacerbate tissue injury 
(Ilmakunnas et al., 2009). However, this study failed to examine neutrophil involvement at later 
time points (>6h) which has been shown in the rodent model to be the time at which neutrophils 
have extravasated and begin to propagate injury in the mouse model (Jaeschke and Smith, 1997; 
Jaeschke et al., 1990).  
 
1.2.3 ISCHEMIC INJURY FOLLOWING LIVER TRANSPLANTATION 
 
1.2.3.1 Introduction 
Liver transplantation remains the only therapeutic option for end-stage liver disease of any 
etiology. Although liver transplantation has become a routine therapy, there are significant post-
operative risks associated with the procedure, such as reperfusion injury and the formation of 
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biliary strictures, which can affect graft survival, morbidity and mortality, and long-term outcome. 
Furthermore, methods to predict which patient will develop these complications are lacking.    
During donor liver procurement and transplantation, the organ experiences no-flow ischemia upon 
procurement, and is stored in a preservative such as University of Wisconsin (UW) solution until 
a recipient is identified (El-Wahsh, 2007). Thus, there is a varying degree of time during which 
the donor liver experiences no-flow ischemia. Unfortunately, this period of ischemia can 
predispose parenchymal and non-parenchymal cells to injury (reperfusion injury) upon warm 
reperfusion, leading to increased risk of graft injury and primary graft failure. Research has shown 
that longer ischemic times lead to greater injury to the liver and an increased risk of complications, 
such as primary graft failure (Marsman et al., 1996; Perez-Daga et al., 2006; van der Vliet and 
Warlé, 2013). Additionally, certain donor liver factors, such as increased levels of steatosis, 
predispose the allograft to increased injury and failure. As a result, these marginal quality livers 
are not frequently used in transplantation, limiting the number of organs available for the life-
saving procedure. Indeed, according to the Organ Procurement and Transplantation Network 
(OPTN), there are currently over 14,000 individuals on a waiting list to receive a transplant despite 
the fact that more than 26,000 transplants have been performed thus far in 2017. Moreover, 
approximately 4,100 people have died while waiting for a transplant. In light of these statistics, it 
is crucial to determine the mechanisms leading to reperfusion injury and biliary stricture following 
human liver transplantation.  
 
1.2.3.2 Cell death following LT 
One of the most basic questions is whether cells die by necrosis or apoptosis following liver 
transplantation. These two modes of cell death differ both in intracellular events as well as 
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histological characteristics. Apoptosis involves activation of caspases and ultimately activation of 
caspase-activated DNAse, which leads to fragmentation of nuclear DNA. Histologically, apoptosis 
is characterized by cellular shrinking, formation of apoptotic bodies, nuclear condensation, and an 
intact cell membrane (Jaeschke and Lemasters, 2003). In contrast, necrosis can be recognized by 
cell swelling, karyorrhexis and karyolysis, and loss of membrane integrity (Jaeschke and 
Lemasters, 2003). Many studies arguing for a relevant impact of apoptosis in IRI rely on terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (Kim et al., 2013; Rao et 
al., 2013). However, because both forms of cell death involve fragmentation of nuclear DNA, 
TUNEL staining alone cannot be used to differentiate the two. Interestingly, the pattern of TUNEL 
staining can give insight into which mode of cell death predominates. We have shown that in cells 
undergoing apoptosis, TUNEL-positive cells appear as punctate stains within the microscopic 
field. However, due to nuclear and cellular lysis that occurs during necrosis, DNA fragments 
diffuse into surrounding areas leading to large, irregularly shaped stained areas.(Jaeschke et al., 
2011; Yang et al., 2014). Since each mode of cell death is carried out by two distinct processes, 
determination of the predominant form of cell death following OLT in humans is necessary to 
identify appropriate therapeutic targets. Furthermore, not much is currently known regarding 
downstream cellular events which lead to hepatocyte injury and death.  
 
1.2.4 LIVER INJURY FOLLOWING HYPOXIC HEPATITIS 
 
1.2.4.1 Introduction 
Hypoxic hepatitis (HH), also called ischemic hepatitis, or ‘shock’ liver, is a clinical condition 
precipitated by prolonged periods of oxygen deprivation to the liver and can have several 
underlying causes. It is characterized by a sudden and rapid increase in ALT (~20X normal) in the 
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absence of any other causes of liver injury, such as viral hepatitis, alcoholic hepatitis, or drug-
induced liver injury. Its prevalence in critically ill patients can reach upwards of 10%. Despite its 
prevalence, little is known about the mechanisms of injury.  
 
1.2.4.2 Clinical Hypoxic Hepatitis 
Typically, the inciting cause for HH involves an episode of cardiogenic, circulatory, or respiratory 
failure leading to decreased oxygen delivery to the liver (Henrion et al., 2003). Hypoxic hepatitis 
represents a serious source of morbidity and mortality, with a prevalence of approximately 10% in 
intensive care patients (Fuhrmann et al., 2010). Treatment of hypoxic hepatitis involves treatment 
of the underlying cause, but mortality can still be as high as 50% (Fuhrmann et al., 2010; Hawker, 
1991; Horvatits et al., 2013).  
In the laboratory, hypoxic hepatitis has been studied in a variety of ways including the hemorrhagic 
shock model. This model involves hemorrhage of the animal to a hypotensive state, thereby 
decreasing oxygen delivery to the liver. In another model, the cardiogenic shock model, a balloon 
catheter is placed in the coronary artery and inflated, leading to cardiogenic shock. A major 
downside to the use of animal models for the study of hypoxic hepatitis is that they are not often 
reproducible. In the most commonly used model, hemorrhagic shock, ALT values don’t always 
reach the level expected during hypoxic hepatitis and even under similar conditions, the degree of 
injury is often vastly different between experiments. Furthermore, the number of underlying 
conditions that can precipitate hypoxic hepatitis in humans, such as respiratory failure/shock, 
aortic dissection, and obstructive sleep apnea (Alcorn and Miyai, 1992; French et al., 1984; 
Henrion et al., 1997, 1999; Leslie et al., 1989; Mathurin et al., 1995; Trilok et al., 2012). far 
outnumber the types of animal models developed for the study of the condition. Thus, subtle 
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differences in the pathophysiology may be missed by relying on animal models which do not 
recapitulate the condition in humans. Furthermore, most laboratory studies of hypoxic hepatitis 
are limited to a specific time point, rather than a complete clinical course. Thus, an alternative 
approach is necessary.  
One possible method to study HH clinically is through the use of the same biomarkers of liver 
injury and death described above. Once a diagnosis of hypoxic hepatitis is made, these biomarkers 
can be measured for an extended time course. Furthermore, they could easily be catalogued and 
classified according to underlying etiology so that patterns in injury can be identified, regardless 
of the underlying cause. 
 
1.3 DRUG-INDUCED LIVER INJURY 
 
1.3.1 Introduction 
Drug induced liver injury is the most common cause of acute liver failure in the US (Chen et al., 
2015; Reuben et al., 2010). Drug induced liver injury can be classified as intrinsic or idiosyncratic; 
the basis for the classification being whether or not the mechanism of injury is intrinsic to the drug 
or not. For the drugs that fall under the ‘intrinsic’ category, either the drug itself or a metabolite, 
has a known deleterious effect on the liver. Thus, injury secondary to the use of these drugs, is 
both predictable and dose-dependent (Fisher et al., 2015). However, the vast majority of drugs 
responsible for DILI fall within the umbrella of idiosyncratic. Idiosyncratic drug induced liver 
injury remains a problem due to the fact that the basis for the injury in susceptible individuals 
remains unknown. There is not likely a single cause for the development of injury in these patients, 
but rather a combination of chemical, genetic, and immunologic factors for the individual which 
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leads to the reaction (Chen et al., 2015; Tailor et al., 2015). Thus, injury with these drugs is both 
unpredictable and non-dose dependent (Fisher et al., 2015).  
Most drugs with a predictable adverse reaction on the liver are screened out before, or during, 
clinical trials (Jaeschke, 2015). An exception to this rule is acetaminophen. While acetaminophen 
is safe at therapeutic levels, it actually represents the most common cause of acute liver failure in 
the United States (Chen et al., 2015; Fisher et al., 2015; Jaeschke, 2015; Reuben et al., 2010). This 
is due in no small part to its availability as an over-the-counter medication, as well as its presence 
in many prescription opioid formulations such as Vicodin® and Percocet® (Bunchorntavakul and 
Reddy, 2013; Herndon and Dankenbring, 2014; Yoon et al., 2016). Many patients on medication 
to manage long-term pain take a combination of these opioid formulations as well as 
acetaminophen, thereby unwittingly overdosing on the drug. Intentional overdose with 
acetaminophen also accounts for a significant number of acetaminophen toxicities.  
 
1.3.2 DILI Secondary to Acetaminophen  
Acetaminophen is a commonly used analgesic and antipyretic (Bunchorntavakul and Reddy, 2013; 
Yoon et al., 2016). It is well tolerated at therapeutic doses (<4g/day) but leads to toxicity at higher 
doses. APAP is metabolized through a combination of Phase I and Phase II detoxifying enzymes. 
In the case of acetaminophen, Phase II metabolism occurs first with the majority of the parent 
compound being conjugated to glucuronide or sulfate, and being excreted as inactive conjugates 
(Larson, 2007). Even at therapeutic doses, a small amount of the parent compound is metabolized 
by cytochrome P-450 enzymes 2E1, 1A2, and 3A4 (Lee et al., 1996; Snawder et al., 1994; 
Thummel et al., 1993). into the toxic and electrophilic intermediate N-acetyl-p-benzoquinone 
imine, or NAPQI (Dahlin et al., 1984). NAPQI is subsequently detoxified by the tripeptide 
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glutathione (Larson, 2007). At higher doses of acetaminophen, the conjugation systems become 
overwhelmed and a much higher percent of the initial dose is shunted through the P-450 system, 
leading to increased NAPQI formation (Du et al., 2013). Although glutathione exists in very high 
concentrations within the cytoplasm, increased NAPQI formation rapidly depletes glutathione 
stores (Lee et al., 1996; Mitchell et al., 1973; Xie et al., 2015a). As an electrophile, NAPQI can 
covalently bind to proteins free-floating within the cytoplasm, or proteins contained on organelle 
membranes forming protein adducts. It has been extensively shown that mitochondrial proteins are 
affected by NAPQI (Cohen et al., 1997; McGill et al., 2012; Qiu et al., 1998; Tirmenstein and 
Nelson, 1989; Xie et al., 2015b). This leads to mitochondrial oxidative stress and JNK activation 
(Du et al., 2015; Gunawan et al., 2006; Henderson et al., 2007; Meyers et al., 1988; Saito et al., 
2010; Xie et al., 2014a). Activated JNK (pJNK) then translocates into the mitochondria and 
amplifies the oxidative stress (Hanawa et al., 2008; Saito et al., 2010). Eventually, the 
mitochondrial membrane permeability transition (MPT) occurs leading to matrix swelling and 
lysis of the outer mitochondrial membrane (Hanawa et al., 2008; Jaeschke et al., 2012a; Kon et al., 
2004; Saito et al., 2010). Mitochondrial lysis leads to the release of apoptosis-inducing factor (AIF) 
and endonuclease G (EndoG) from the intermembrane space (Bajt et al., 2004, 2006; Cover et al., 
2005). These two endonucleases then translocate to the nucleus leading to fragmentation of nuclear 
DNA and, ultimately, hepatocyte cell death by oncotic necrosis (Bajt et al., 2011; McGill et al., 
2012). 
 
1.3.3 Importance of hepatocyte models 
While the mechanisms of liver injury following acetaminophen toxicity are well described in mice 
and man, knowledge into the mechanisms leading to liver injury following idiosyncratic drug 
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induced liver injury is lacking. Furthermore, hepatotoxicity is the most common cause of drug 
failure during development or clinical trials. Thus, to prevent a significant expenditure of financial 
and other resources, drug development companies must be able to determine early on in the 
development process which drugs will cause hepatotoxicity, and which drugs will not. Therefore, 
convenient, reliable, and inexpensive models, such as cell culture models, must be developed to 
accurately identify hepatotoxic drugs before the clinical phase.  
One of the more commonly used hepatocyte cell line is the HepG2 cell line. Since the discovery 
of this cell line in 1979 (Aden et al., 1979), it has been used extensively in research, including drug 
metabolism studies. One major drawback, however, is that the HepG2 cell line, while beneficial 
for many aspects of liver study, do not possess a full complement of the drug metabolizing 
enzymes, cytochrome-P450s (Wilkening et al., 2003), limiting their usefulness for these studies. 
Another human hepatoma cell line, HepaRG, was identified and shown to express a level of 
cytochrome P450s more consistent with primary human hepatocytes (Aninat et al., 2006; Gripon 
et al., 2002), making them a superior choice for studies of drug metabolism, relative to HepG2. 
While primary human hepatocytes remain the gold standard for hepatocyte cell culture studies, 
they are only sporadically available, require specialized isolation techniques and do not tolerate 
the freeze/thaw cycle well (Rijntjes et al., 1986). Thus, HepaRG cells provide an attractive 
alternative to primary cells. Even still, lengthy growth and differentiation process limits their 
usefulness for quick studies. To overcome this, a pre-differentiated cryo-preserved HepaRG cell 
line was developed, dramatically decreasing the growth period, and increasing their usefulness.  
The final chapter of this dissertation will be dedicated to the exploration of the use of the pre-
differentiated HepaRG cell line for the studies of drug metabolism, specifically for studies of 




2. PLASMA BIOMARKERS OF ISCHEMIA-REPERFUSION 
INJURY IN HUMAN LIVER TRANSPLANTATION 
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2.1 INTRODUCTION:  
Liver transplantation (LT) remains the only therapeutic option for patients with end-stage liver 
disease (ESLD). During LT, the donor liver undergoes a period of ischemia during harvest and 
cold storage up until the time of reperfusion in the recipient. This ischemic period consists of both 
warm and cold ischemia. Paradoxically, the return of blood flow to the ischemic organ predisposes 
it to injury.  
Ischemia-reperfusion injury (IRI) has been described in multiple organs. In the mouse liver, the 
reperfusion period itself is relatively well tolerated as demonstrated by low levels of ALT for 
several hours following reperfusion (Yang et al., 2014). However, this low level of injury 
ultimately initiates an inflammatory cascade through the release of cellular debris, activation of 
Kupffer cells, and finally, the recruitment of neutrophils, which are responsible for necrotic cell 
death (Ellett et al., 2009; Jaeschke and Farhood, 1991b). In human patients undergoing liver 
transplantation, relatively little is known about IRI. This is due, in part, to the fact that invasive 
biopsies at extended time-points following transplantation are not possible in these patients. 
Therefore, a non-invasive method for describing IRI in human transplant patients is required. 
Recently, circulating biomarkers have been used to describe molecular mechanisms and events 
following several types of liver injury, such as cholestasis and drug induced liver injury (DILI) 
(Antoine et al., 2012; McGill and Jaeschke, 2014; Woolbright et al., 2013). These biomarkers 
accurately describe both mode and mechanisms of cell death during these conditions, and also 
show promise in predicting outcome (McGill et al., 2012). Previous results from our laboratory 
has demonstrated that these same biomarkers can be used to accurately describe the events 
occurring following IRI in rodents (Yang et al., 2014). Because these biomarkers are non-invasive, 
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and can be easily measured in plasma, they represent an ideal technique to describe the events 
contributing to liver injury following LT in humans.  
While other groups have also used this approach, their studies have been limited to earlier 
reperfusion times (Ilmakunnas et al., 2008, 2009; Pesonen et al., 2000; Ulukaya et al., 2010), 
following transplantation. However, in the rodent model of IRI, a model often used to recapitulate 
human transplantation, peak neutrophil infiltration and extravasation doesn’t occur until 6 hours 
post reperfusion, and peak injury doesn’t occur until 24 hours post reperfusion. Therefore, a more 
comprehensive time course is necessary to fully understand the events which occur following LT 
in humans. In addition, there are currently no studies which evaluate multiple biomarkers for a 
prolonged time course. Thus, an accurate clinical picture of the cellular events that occur several 
days following transplantation is lacking. Therefore, we sought to obtain a comprehensive 
characterization of the cellular events which occur following liver transplantation by evaluating 
biomarkers known to accurately describe extent of injury (ALT, miRNA-122), mode of cell death 
(cytokeratin-18), and mitochondrial involvement (GDH, mtDNA), in patients undergoing liver 
transplantation before, during, and up to 72 hours following the procedure. Furthermore, we 
evaluated the role of neutrophils in the post-reperfusion injury process by evaluating CD11b 
expression, ROS production, and phagocytic capability, all parameters of neutrophil activation.  
We found that in contrast to the mouse model of IRI, most of the injury occurs within several hours 
of reperfusion. Importantly, we found no evidence for the involvement of neutrophils in this 
process, but rather a trend toward the decrease of neutrophil involvement. Thus, we conclude that 




2.2 PATIENTS AND METHODS: 
Study Design: All consenting patients undergoing liver transplantation for any reason at the 
University of Kansas Hospital were included in this study. Blood from patients enrolled in this 
study was collected at the following times: Pre-OLT (6hrs before procedure), anhepatic period, 
0.25, 0.5, 1, 6, 12, 24, 48, and 72 hours post-reperfusion. At each time point, blood was collected 
in a red top tube (no additives) for serum, and a green top tube (heparin) or pink top tube (EDTA) 
for plasma. Upon collection, blood was stored at 4oC until procurement by study personnel, at 
which point blood tubes were centrifuged and plasma/serum was aliquoted and stored at -80oC 
until use. All procedures conducted in this study were done with approval by, and in accordance 
with, the Institutional Review Board at the University of Kansas.  
 
Biochemistry: ALT was measured using a commercially available kit (Pointe Scientific, Roche, 
IL) according to the manufacturer’s instructions. GDH was measured using the modified method 
of Passonneau and Lowry as previously described (McGill et al., 2012). 
 
Mitochondrial DNA: DNA from serum was isolated using the QiaAMP Mini Blood Kit (Qiagen, 
USA) according to the manufacturer’s instructions. Isolated DNA was then subjected to qPCR 
using primers for the mitochondrial-DNA specific gene cytochrome C oxidase subunit III (CytC; 
Fwd-ATGACCCACCAATCACATGC, Rev-ATCACATGGCTAGGCCGGAG). Quantification 
of mtDNA was compared to a standard curve consisting of known amounts of DNA isolated from 




Nuclear DNA fragments: Nuclear DNA fragments were measured using a commercially available 
cell death detection kit (Roche, Indianapolis, IN) according to the manufacturer’s instructions. 
This ELISA kit uses a primary anti-histone antibody and a secondary anti-DNA antibody. Upon 
addition of substrate, the absorbance at 405nm over 1 hour was measured and compared to control 
(pre-OLT sample for each patient). 
 
miRNA-122: qPCR was used to measure miRNA levels as described previously (Starkey Lewis et 
al., 2011). 
 
HMGB1 and cytokeratin: Total HMGB1 and cytokeratin-18 (cleaved and full-length) were 
measured by LC-MS/MS as described previously (Antoine et al., 2009). 
 
Neutrophil assays: All neutrophil assays were performed within 6 hours of the blood draw. Neutrophil 
activation was measured using flow cytometry to identify neutrophils expressing the CD11b surface 
marker. Whole blood was incubated on ice with saturating concentrations of PE-labeled anti-CD11b 
antibody. Red blood cells were subsequently lysed and neutrophils expressing CD11b were identified via 
flow cytometry. The oxidative burst assay was used to measure production of ROS from activated 
neutrophils. Briefly, whole blood was incubated with PBS, PMA, or E. coli at 37oC for 10 min. DHR-123 
was then added, followed by a second ten minute incubation period. The samples were washed, red cells 
lysed, centrifuged, and the pellet reconstituted. In the presence of ROS, DHR-123 is converted to its 
fluorescent metabolite rhodamine-123. Flow cytometry was then used to quantitate production of ROS as 
a function of increased fluorescence. The neutrophil phagocytosis assay was used to assess neutrophil 
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function. Whole blood was incubated with FITC-labelled E-coli for 15 minutes. Flow cytometry was used 






Patient Data. Consenting patients undergoing transplant for any etiology of ESLD were included 
in this study. The age of patients in this study ranged from 19 to 69 (mean = 57) and consisted of 
47 males and 25 females. The most common diagnosis was viral hepatitis (HCV) with or without 
the presence of other confounding factors. Patient data is summarized in Table 2.3.1. Data from 
one consenting patient was excluded due to immediate post-operative complications (thrombosis). 
Every attempt was made to collect each time point for every patient but some time points were 
missed in order to maintain standard of care. The most commonly missed time point was +72 
hours. 
 
Time course of injury following LT. We first set out to describe the time course of injury following 
OLT in humans. In contrast to the rodent model of IRI, in which ALT remains low during the early 
time point and peaks at later time points, we found a sharp rise in ALT at 1hr (44649 U/L) 
followed by a gradual decline over the next 72 hours (Figure 2.3.1A). Previous studies have 
demonstrated that miRNA-122 is a more sensitive indicator of liver injury than ALT (Laterza et 
al., 2009), so we measured this biomarker to confirm this pattern of injury. Again, we found, a 
similar pattern: a sharp rise to maximum injury (11.71.7 U/L) at 1 hour followed by a gradual but 
steady decline over the next 72 hours (Figure 2.3.1B). The similarity between ALT and miRNA-
122 is best observed when compared directly (Figure 2.3.1C).  
 
Mitochondrial injury during OLT. Previous studies have implicated mitochondrial injury as an 
initiator of cell death following periods of ischemia (Lemasters et al., 1997; Theruvath et al., 2008). 
To test the possibility that injury following OLT is a result of mitochondrial injury, we measured  
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  Table 2.3.1 Patient Data 
Table 2.3.1. Patient Data. Representative data for patients undergoing orthotopic liver transplantation 












































































































Figure 2.3.1. Time course of reperfusion injury following transplantation. Plasma levels of (A) ALT 
and (B) miRNA-122 from ≤6hrs before to 72 hours after liver transplantation. (C) ALT and miRNA-122 
for these same time points on the same graph to show correlation of miRNA-122 and ALT. Data from 
each time point is represented as average ± SEM for 43-74 patients (ALT) or 18-25 patients (miRNA-
122). Horizontal dashed bar represents average of healthy volunteers. 
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the matrix macromolecules glutamate dehydrogenase and mitochondrial DNA. Upon 
mitochondrial injury and cell death, these macromolecules would be released into the sinusoids 
and systemic circulation. Interestingly, we found that peak mtDNA for CytC reached 7.51.3 
ng/ml and occurred 1 hour following reperfusion (Figure 2.3.2A). In contrast, peak levels of GDH 
(15327 U/L) didn’t occur until 24 hours post-reperfusion (Figures 2.3.2B&C).  
 
Nuclear DNA fragmentation. In addition to GDH and mtDNA, mitochondrial injury leads to the 
release of endonuclease G, causing nuclear fragmentation and cell death (McGill et al., 2012). To 
explore the relationship between mitochondrial injury and nuclear DNA fragmentation following 
transplantation, we measured the amount of DNA fragments in plasma from these patients. As 
with ALT, miRNA-122, and mtDNA, we found a sharp increase in DNA fragmentation at 1 hour 
post-reperfusion (~700 fold increase vs. control) which gradually reached baseline over the next 3 
days (Figure 2.3.2D). Taken together, these data indicate that the majority of injury following OLT 
is due to ischemia, rather than reperfusion injury.  
 
Necrosis, not apoptosis, is the predominant mode of cell death. Despite substantial evidence to the 
contrary, many studies still point to apoptosis as the primary mode of cell death following ischemic 
injury. To differentiate between these two forms of cell death in the current study, we used levels 
of cytokeratin-18, an intermediate filament protein. During apoptosis, CK-18 is cleaved by 
caspases into its shorter form, ccK-18. However, during necrosis, the full-length form (FK-18) is 
passively released. We found a dramatic increase in both the caspase-cleaved and full-length forms 
of cytokeratin (2950580 vs 29,3004200 U/L, respectively) 1 hour following reperfusion 
(Figures 2.3.3A&B). While the increase in ccK-18 was unexpected, when compared to the FK-18  
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Figure 2.3.2. Mitochondrial biomarkers following transplantation. Plasma levels of (A) 
Cytochrome C oxidase subunit III mtDNA and (B) GDH from ≤6hrs before to 72 hours after liver 
transplantation. (C) mtDNA and GDH for these same time points on the same graph demonstrates lack 
of correlation between mtDNA and GDH. (D) Nuclear DNA fragments from ≤6hrs before to 72 hours 
after liver transplantation. Data from each time point is represented as average ± SEM for 44-59 (CytC) 
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Figure 2.3.3. Necrosis predominates following reperfusion. Plasma levels of (A) caspase cleaved (ccK-
18) and (B) full length (FK-19) cytokeratin-18 from ≤6 hours before to 72 hours after liver transplantation. 
(C) Comparison of ccK-18 and FK-19 showing significant elevation of FK-18 over ccK-18 at each post-
reperfusion time point except 72hr. ‘Pre’ and ‘Anh’ represent the pre-OLT and anhepatic blood draws, 
respectively. (D) Plasma levels of nuclear DNA fragments for the same time points. Data from each time 
point is represented as average ± SEM for 18-25 patients. Horizontal dashed line represents average of 




at each time point, the contribution of ccK-18 to overall cell death is only approximately 10%. 
(Figure 2.3.3C). Furthermore, the nuclear protein HMGB1 also peaks at this time point (15.72.4 
ng/ml). Since HMGB1 is passively released during necrosis, this increase gives further evidence 
to the necrosis at this time point (Figure 2.3.3D). Taken together, this data indicates that necrosis, 
rather than apoptosis predominates during all time points.  
 
No evidence for neutrophil involvement in OLT injury. In the rodent model of IRI, liver injury is 
largely dependent on Kupffer cell activation and neutrophil recruitment/activation (Ellett et al., 
2009; Jaeschke and Farhood, 1991b; Nace et al., 2013). Therefore, we set out to determine the 
extent to which neutrophils are involved in injury following LT in humans. To do this, we 
measured neutrophil activation as determined by CD11b expression, (Figure 2.3.4A), ROS 
production (Figure 2.3.4B), and phagocytic capability (Figure 2.3.4C). In contrast to markers of 
injury and cell death, which peaked early and gradually subsided, we found no significant change 
over the 72 hours in these parameters following LT. In fact, all markers of neutrophil activity were 
observed to be elevated initially, and then trend downward during this period. When compared to 
ALT activity, there was no significant change in neutrophil activity at the same time as peak ALT 
concentration suggesting liver injury is not a result of neutrophil activation (Figure 2.3.4D). Taken 
together, these data suggest no relevant role for neutrophils in the injury process following OLT, 

















































































































Figure 2.3.4. Assessment of CD11b expression and phagocytosis following transplantation. 
Measurement of (A) CD11b expression and (B) phagocytic activity in neutrophils following OLT in human 
patients at various time points before and after reperfusion. Representative histogram showing shifts in (C) 
CD11b expression or (D) phagocytosis at 6 hours post-reperfusion relative to healthy volunteers. (E) 
Comparison of neutrophil activation (as measured by CD11b expression) and ALT, demonstrating that 
peak ALT injury occurs in the absence of increased neutrophil activity. Data from each time point is 
represented as average ± SEM for 6-7 patients (CD11b and phagocytosis) or 43-74 patients (ALT). 





In the present study, we set out to examine the cellular events leading to reperfusion injury in 
humans following OLT. To do this, we used several circulating plasma biomarkers which are 
predictive of mode and mechanism of cell death in other disease models, as well as the mouse 
model of IRI (Antoine et al., 2012; McGill and Jaeschke, 2014; Woolbright et al., 2013; Yang et 
al., 2014). Because the role of neutrophils following OLT in humans is currently unknown, we 
also measured markers of neutrophil activation including CD11b expression, phagocytic 
capability, and ROS production. 
Based on the results of this study, it appears that there is very little reperfusion injury in the average 
transplant patient; most of the observed increase in ALT is likely a result of the ischemic period. 
Previous studies have demonstrated that during ischemia, the lack of oxygen delivery causes the 
hepatocyte to switch from aerobic metabolism to anaerobic metabolism leading to an increase in 
lactic acid concentrations, a rapid decrease in ATP levels, decreased intracellular pH, and an 
inability of the cell to maintain homeostasis (Barbiro et al., 1998; Lemasters et al., 1987). As a 
result of these changes, a small percentage of cells die during ischemia. However, the majority of 
cell death is caused during the reperfusion period during which osmotic forces drive extracellular 
fluid into the cell in an attempt to normalize the metabolic perturbations which occurred as a result 
of ischemia. This results in cellular swelling and oncotic necrosis.  
In our study, nearly all of the markers of injury peak very shortly after reperfusion, which is in 
direct contrast to the rodent model of IRI in which injury peaks 12-24 hours post-ischemia. This 
rapid peak likely represents a ‘wash-out’ period where reperfusion of the previously ischemic liver 
causes release of these markers from necrotic cells. However, the use of preservative solutions and 
cold storage minimize the degree of damage (Vine et al., 1989), thus, the overall degree of injury 
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is quite low relative to models of warm ischemia, such as the rodent IRI model, and hypoxic 
hepatitis (Weemhoff et al., 2017). This also explains the lack of a robust immune response in that 
neutrophils are recruited to eliminate cellular debris from necrotic cells and in the process, release 
ROS, such as hypochlorous acid (Hasegawa et al., 2005), which accidentally kill injured 
hepatocytes which may have otherwise recovered from the initial hypoxic insult. In the warm 
ischemia mouse model, there is extensive injury and thus a robust immune response. Furthermore, 
it could be assumed that the number of unhealthy, but not dead, hepatocytes are greater in models 
of warm ischemia than in patients following OLT as a result of the use of preservative solutions 
which reduce the ionic changes described above, decreased operative time, and decreased storage 
time. 
Previous studies have suggested that the mitochondria play a key role in ischemic injury through 
opening of the MPTP (Kim et al., 2003; Lemasters et al., 1997; Theruvath et al., 2008). Our data 
supports this hypothesis in that there is an elevation of mitochondrial specific macromolecules 
DNA and GDH, which would only be expected to be present in serum if mitochondrial rupture has 
occurred. Interestingly, whereas mtDNA shows a rapid increase and decline, GDH actually shows 
a rapid, yet sustained increase (Figures 2.3.2A & 2.3.2B). However, since there is no significant 
difference between 6 and 24 hours, and a downward trend is noted after 6 hours, this discrepancy 
could be attributed to different half-lives of the macromolecules in plasma.  
In contrast to the rodent model of IRI, in which significant injury occurs approximately 6 hours 
after reperfusion and is correlated with neutrophil infiltration (Jaeschke et al., 1990), human 
patients undergoing OLT experience peak injury much earlier (approximately 1 hour post-
reperfusion) and does not correlated with an increase in neutrophil activity (Figures 2.3.1A and 
2.3.4E). In fact, in these patients, markers of neutrophil activity actually tend to decrease following 
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reperfusion. This unexpected finding underscores the difference between the two models of IRI. 
In the rodent model, maximum damage is created by occlusion of the portal triad supplying the 
left lateral and medium lobe, and the liver undergoes warm ischemia, while during transplantation, 
every effort is made to minimize tissue injury though the use of preservatives such as University 
of Wisconsin solution, minimizing operative time, and optimizing donor liver for the recipient. 
Importantly, livers stored in UW solution prior to transplant are stored at sub-normothermic 
temperatures, which slows basal metabolic rate and delays the depletion of ATP (Jain et al., 2008; 
Reckendorfer et al., 1992). Thus, the two major inciting causes of reperfusion injury in the mouse 
model are ameliorated in human patients. Therefore, very little injury occurs, which would not be 
expected to generate a robust inflammatory response.  
In addition to storage and operative protocols which minimize damage, other factors may play a 
role in the pattern of neutrophil activation observed in the current study. During experimental 
induction of IRI in the mouse model, the livers of the ischemic mice are healthy but then greatly 
injured, leading to neutrophil infiltration and exacerbation of injury (Jaeschke et al., 1990). On the 
other hand, human patients preparing to receive a liver transplant already have injured livers, which 
might explain why pre-operative neutrophil activity is already high (Figure 2.3.4A). Following 
transplantation, the diseased liver is replaced with a healthier liver, causing neutrophil activity to 
actually decrease over the first few days. In addition, many of these patients are on 
immunosuppressive medications which may contribute to the tapering of neutrophil activation 
observed following reperfusion.  
A final point of interest in this study is the observation that necrosis, not apoptosis predominates 
during all time points following reperfusion in OLT. While many studies point to apoptosis as the 
primary mode of cell death following ischemia, many of these studies rely solely on TUNEL 
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staining, which is not specific for apoptotic cell death. Histopathology can be used to differentiate 
between the two forms, but this is not practical for human patients following OLT. Thus, the 
cytokeratin-18 assay can be used. During apoptosis, caspases cleave cytokeratin-18 into a 
fragmented form, but during necrosis, cytokeratin-18 is passively released in its full-length form. 
Thus, the degree of elevation of each form can indicate which mode of cell death is predominating. 
In the current study, it is clear that necrosis, not apoptosis, is the mode of injury following 
reperfusion. This is in direct contrast with previous studies showing protection against injury when 
an experimental caspase inhibitor is added to the preservation solution (Baskin-Bey et al., 2007). 
However, protection is only afforded if added to the preservative solution, and at a concentration 
high enough to affect other proteases which may be active during necrosis (Schotte et al., 1999). 
Thus, therapeutic efforts aimed at minimizing injury should be directed towards minimizing 
necrosis, rather than apoptosis. 
In the current study, we have characterized the mechanisms and mode of cell death following liver 
transplantation in humans. Despite minimal injury, there is still evidence for mitochondrial 
involvement in cellular injury which is in agreement with other studies. Furthermore, we have 
shown that necrosis, rather than apoptosis predominates following OLT. Overall, the current study 

































3. PLASMA BIOMARKERS TO STUDY MECHANISMS OF LIVER 





Hypoxic hepatitis (HH) is a condition resulting from prolonged periods of hypoxia to the liver. 
Hypoxic hepatitis is recognized clinically by a hypoxic insult accompanied by sharp increases in 
plasma transaminase activity to >20 times normal, and lack of other confounding etiologies of 
liver disease, such as viral or drug-induced hepatitis (Henrion et al., 2003; Horvatits et al., 2013). 
Typically, the inciting cause for HH involves an episode of cardiogenic, circulatory, or respiratory 
failure leading to decreased oxygen delivery to the liver (Henrion et al., 2003). Hypoxic hepatitis 
represents a serious source of morbidity and mortality, with a prevalence of approximately 10% in 
intensive care patients (Fuhrmann et al., 2010). HH resolves with treatment of underlying causes, 
but mortality can reache 50-60% within one month (Fuhrmann et al., 2010; Hawker, 1991; 
Horvatits et al., 2013).  
Despite the prevalence and mortality of HH, very few studies have examined the cellular 
mechanisms underlying liver injury, in part due to the lack of an animal model. The most relevant 
model employed experimentally is the hemorrhagic shock/resuscitation model in which rodents 
are hemorrhaged to a hypotensive state (low flow ischemia) for a period of time, followed by a 
resuscitation period, after which cellular mechanisms of liver injury can be assessed. A major 
problem with this model is that liver injury does not always approach the degree of injury seen 
during clinical cases of HH, during which ALT levels easily exceed 20 times normal (Jaeschke 
and Farhood, 2002; Wetzel et al., 2014; Zuckerbraun et al., 2005), indicating that the model does 
not completely recapitulate what is occurring in a clinical setting. Additionally, HH can be 
precipitated by a number of causes other than hemorrhagic shock (Henrion et al., 2003). 
Furthermore, most of these studies are limited in that they evaluate a time point shortly after 
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(<6hrs) resuscitation, rather than a prolonged time course. Therefore, a different approach to study 
the mechanisms of injury during HH is needed. 
One such approach is the use of mechanistic biomarkers of liver injury, such as mitochondrial 
DNA, microRNA-122 (miRNA-122), total and acetylated HMGB-1 (acHMGB1), and the ratio of 
caspase-cleaved to full-length cytokeratin-18. Our laboratory and others have previously used this 
approach to characterize both modes of cell death (apoptosis vs. necrosis) and cellular mechanisms 
of liver injury in ischemia/reperfusion injury in mice, as well as acetaminophen toxicity and 
cholestasis in both mice and humans (Antoine et al., 2012; McGill et al., 2012; Starkey Lewis et 
al., 2011; Woolbright et al., 2015; Yang et al., 2014). In addition, a previous study has 
demonstrated that miRNA-122 may be a more sensitive marker of liver injury during HH in a 
porcine model of cardiogenic shock (Andersson et al., 2012). However, to date, no studies have 
employed the use of these biomarkers to characterize the mechanisms of liver injury following HH 
in humans. Therefore, the aim of the current study was to assess the mechanisms of liver injury 
following HH using circulating plasma biomarkers in order to better understand cellular 





3.2 PATIENTS, MATERIALS AND METHODS 
 
Patient Characteristics and Study Design: Subjects with HH were selected from 266 patients who 
presented to Banner-University Medical Center Phoenix with initially suspected acetaminophen 
(APAP) toxicity. However, only those patients with peak plasma ALT > 1,000 IU/L whose hepatic 
necrosis was not caused by APAP (as determined by plasma APAP and APAP-protein adduct 
levels), medical history demonstrating a definitive history or strong likelihood of 
hypotension/shock, and who were subsequently diagnosed with HH were selected (total of 14 
patients). A total of 15 age- and gender-matched subjects with APAP toxicity were selected among 
inpatients at the University of Kansas Medical Center or Banner-University Medical Center 
Phoenix as comparison. Patients with comorbidities contributing to liver injury (such as alcoholism 
or viral hepatitis) were excluded. Blood was obtained upon admission after informed consent, and 
then approximately every 24 hours. Because duration of hospitalization differed for each patient, 
for the purposes of this study, the day of peak injury (as assessed by clinically measured ALT 
levels) was considered ‘day 0’. Following blood collection, blood tubes were centrifuged, plasma 
collected, frozen, and sent to the University of Kansas Medical Center or the University of 
Liverpool for analysis. All biochemical parameters reported are averages of maximum values, not 
necessarily values at the time of peak ALT. All patient samples were procured with approval by, 
and in accordance with the Institutional Review Board at both the University of Kansas and Banner 
Health Center. 
 
Animals. C57Bl/6J mice were purchased from Jackson Laboratories (Bar Harbor, Maine) and 
treated with 700 mg/kg galactosamine/100 µg/kg Salmonella enteritidis endotoxin (Gal/ET). After 
6 h, blood was obtained for measurement of plasma caspase-3 activities as described (McGill et 
48 
 
al., 2012). All experimental protocols were approved by the Institutional Animal Care and Use 
Committee of the University of Kansas Medical Center. 
 
Biochemistry. ALT values reported for all subjects from Banner-University Medical Center 
Phoenix were from the hospital laboratory. ALT values for APAP patients from University of 
Kansas were measured in our laboratory using a commercially available kit (Pointe Scientific; 
Canton, MI). GDH activity was measured in our laboratory as previously described (McGill et al., 
2012).  
 
Mitochondrial DNA. Mitochondrial DNA was measured as previously described (McGill et al., 
2012). Briefly, total DNA was isolated from plasma using the QIAamp DNA Blood Mini Kit 
(QIAGEN) and subjected to RT-qPCR using primers for human mtDNA specific NADH 
dehydrogenase (ND1: Fwd: ATACCCATGGCCAACCTCCT Rev: 
GGGCCTTTGCGTAGTTGTAT). Absolute quantification was achieved with use of a standard 
curve using known amounts of DNA from mitochondrial pellets obtained from primary human 
hepatocytes, isolated and processed as described previously (Xie et al., 2014a).  
 
Nuclear DNA Fragments. Nuclear DNA fragments from HH subjects and healthy volunteers were 
measured using the cell death detection ELISA kit (Roche, Indianapolis, IN) according to the 
manufacturer’s instructions (McGill et al., 2012). Change in absorbance over time at 405 nm was 




HMGB1 and cytokeratin-18. HMGB1 (total and acetylated) and cytokeratin-18 (cleaved and full-
length) were measured by LC-MS/MS as previously described (Antoine et al., 2012, 2013). 
 
miRNA-122. miRNA levels were measured by qPCR as previously described (Antoine et al., 2013; 
Starkey Lewis et al., 2011) and normalized to let-7d, is stably expressed in patients with acute liver 
injury and healthy volunteers (Antoine et al., 2013; Qi et al., 2012).  
 
Caspase Activity. Caspase activity was measured using a fluorometric assay as described (Jaeschke 
et al., 1998). Briefly, plasma was added to caspase substrate (DEVD; 50µM final concentration) 
with or without inhibitor (Z-VAD-fmk; 10µM final concentration). Fluorescence was measured 
(excitation 480nm and emission 560nm) over one hour. Caspase activity was measured by 
subtracting activity with inhibitor from activity without inhibitor. 
 
Cytokine Measurements. Plasma cytokines were measured by a multi-plex ELISA (Millipore, 
Billerica, MA) according to the manufacturer’s instructions. Quality controls were run in duplicate 
with the samples and found to be within the normal range.  
 
APAP-CYS Adduct Measurements. Plasma levels of APAP-CYS were measured using HPLC-
ECD as previously described (James et al., 2009; Xie et al., 2015a). Time points as close as 
possible to Day 0 (peak ALT) for both APAP and HH patients were used in this analysis. 
Statistics. All data are expressed as average ± SEM. Statistics was performed using 1-way ANOVA 





Hypoxic hepatitis causes profound liver injury. All patient data is represented in Table 3.3.1. We 
first measured the time course of injury in these patients to ensure they fit the clinical profile of 
HH. We found that plasma ALT activities rapidly rose to peak injury (4082±606 U/L; Figure 
3.3.1A) and steadily decreased over the next 5 days. When compared to healthy volunteers (HV), 
the difference in ALT was significantly higher at peak injury (4082±606 vs. 23.8±3.1 U/L) but not 
significantly different from patients with liver injury from APAP overdose (4082±606 vs. 
5744±588 U/L; Figures 3.3.1A&B). Because ALT is not specific to the liver, and HH affects all 
organs simultaneously, we measured levels of the liver-specific microRNA-122 to ensure the 
majority of the ALT was from liver injury. Again, in HH patients, we found a dramatic increase 
to peak injury followed by a gradual but steady decline (Figure 3.3.1C). When compared to HV, 
levels of miRNA-122 in HH patients were significantly higher than controls (13.2±3.1 vs. 
0.52±0.26, respectively; Figure 3.3.1D). To confirm liver injury was not caused by APAP, plasma 
levels of APAP-CYS were measured in both APAP and HH patients (Figure 3.3.2). 
 
Hypoxic hepatitis causes hepatocellular necrosis. To differentiate whether liver injury is caused 
by necrosis or apoptosis, we measured plasma levels of full-length and caspase-cleaved 
cytokeratin-18. We observed a rapid increase in both forms of cytokeratin-18 at the time of peak 
ALT, followed by a gradual and steady decline over 5 days (Figure 3.3.3A&B). However, the 
magnitude of increase in the full-length form was approximately 18-fold higher than the caspase-
cleaved form (45837±12085 vs 2528±1074) at the time of peak ALT. Furthermore, levels of full-
length cytokeratin-18 were significantly higher than caspase-cleaved cytokeratin-18 at each time 





Table 3.3.1 Patient Data 
Table 3.3.1. Patient characteristics. Clinical parameters and other characteristics of patients diagnosed with HH 
and acetaminophen toxicity. Peak values for AST, ALT, creatinine and bilirubin are reported as average ± SEM of 
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Figure 3.3.1. Time course of injury following hypoxic hepatitis. (A) Plasma levels of ALT in both HH 
and APAP patients from -1 to +5 days after peak injury. (B) Dot histogram comparing plasma levels of 
ALT between HH patients and HV or patients with APAP toxicity at the time of peak ALT. (C) miRNA-
122 for patients with HH are shown from -1 to +5 days after peak injury. (D) Dot histogram comparing 
plasma levels of miRNA between HH patients and HV at the time of peak ALT. Line graph data are 




































Figure 3.3.2 Plasma APAP-CYS adducts. Comparison of 
plasma APAP-CYS protein adducts in HH or APAP overdose 
patients at the time of peak injury. Data are expressed as average 
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Figure 3.3.3. Necrosis predominates during hypoxic hepatitis. Plasma levels of (A) full-length 
cytokeratin-18 and (B) caspase-cleaved cytokeratin-18 from -1 to +5 days after peak injury. (C) Total 
cytokeratin-18 levels during the same time course demonstrating the relative contributions of each form 
of cytokeratin. (D) Caspase activity in plasma at various time points following peak injury. As positive 
control for apoptosis, plasma samples were obtained from mice treated with galactosamine/endotoxin for 
6 h. Data are represented as average ± SE. * = p<0.05. 
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However, because there was an increase in caspase cleaved cytokeratin-18, we measured caspase 
activity in the plasma but found no measureable caspase activity in these samples (Figure 3.3.3D). 
Plasma from galactosamine//endotoxin (Gal/ET)-treated animals served as controls for 
parenchymal cell apoptosis (Jaeschke et al., 1998). The readily detectable caspase-3 activity in 
these animals suggested that if significant caspase-dependent apoptotic cell death occurs, plasma 
caspase-3 activity can be measured.  
 
Mitochondrial injury occurs in HH. Numerous in vitro studies suggest mitochondria are targets of 
ischemia-reperfusion injury (Lemasters et al., 1997). To test this hypothesis in these patients, we 
measured levels of the mitochondria-specific biomarkers GDH and mitochondrial DNA (mtDNA). 
Because these macromolecules are located within the mitochondrial matrix, only mitochondrial 
damage would be expected to lead to their release in plasma (McGill et al., 2012). Accordingly, 
we found an increase in GDH which closely mimicked the increase in ALT – that is, a rapid 
increase at the time of peak ALT (1381±229) followed by a gradual but steady decline (Figures 
3.3.4A, 3.3.5, 3.3.6, & 3.3.7). Similarly, plasma levels of mtDNA as measured by RT-PCR of the 
cytochrome c oxidase (CytC) gene showed a similar downward trend following peak injury (Figure 
2.3.4C). Interestingly, neither levels of GDH nor CytC mtDNA in plasma of HH patients were 
elevated compared to APAP overdose patients (Figures 3.3.4B & D).  
 
Nuclear DNA fragmentation in HH. Because mitochondrial injury during necrosis releases 
endonucleases leading to nuclear DNA fragmentation and cell death (Bajt et al., 2006), we 
measured plasma levels of nuclear DNA fragments. Our results show an increasing concentration 
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Figure 3.3.4. Mitochondrial injury occurs in hypoxic hepatitis. Plasma levels of (A) GDH and (C) 
cytochrome c oxidase (CytC) mtDNA for patients with HH or APAP overdose shown from -1 to +5 days 
after peak injury. Data are presented as average ± SE. Dot histograms comparing plasma levels of (B) GDH 
and (D) CytC mtDNA between HH patients and HV or patients with APAP toxicity at the time of peak 
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Figure 3.3.5 Time course of hepatocellular and mitochondrial 
injury. Comparison of plasma levels of ALT (hepatocellular 
injury) and GDH (mitochondrial injury) in hypoxic hepatitis 
patients from one day before to 5 days after peak ALT. Data are 
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P=<0.05 
Figure 3.3.6. Regression analysis of biomarkers. Linear regression analysis of (A) miR-122, (B) FK-
18, (C) ccK-18, and (D) GDH with ALT. Data is presented from the day before to 5 days after peak injury 






Figure 3.3.7. Regression analysis of biomarkers. Linear regression analysis of (A) CytC, (B) Nuclear 
DNA Fragments, (C) Total HMGB1, and (D) Acetylated HMGB1 with ALT. Data is presented from the 
day before to 5 days after peak injury as measured by ALT. * = p<0.05 vs. control.  
ALT (U/L)


















































































































 (1444±182%; Figure 3.3.8A). As with GDH, this time course of injury closely mimics that of 
ALT. We then compared the levels of nuclear DNA fragments to those observed in APAP patients. 
As with GDH and mtDNA, there was no significant difference between HH and APAP patients 
(1444±182 vs. 2531±552%, respectively; Figures 3.3.8A & B). 
 
The inflammatory response does not exacerbate HH in later stages. HMGB1 is a nuclear protein 
that sits in the minor grove of DNA and modulates transcription of numerous genes. HMGB1 can 
be either passively released during necrosis or actively secreted in its acetylated form by 
inflammatory cells. Therefore, the two forms of HMGB1 can provide information on the mode of 
cell death as well as possible inflammatory cell activation during injury. To confirm necrosis as 
the mode of cell death, we measured total levels of HMGB1 and found a similar pattern of change 
over the course of injury as all other parameters measured thus far (Figure 3.3.8C). These data are 
consistent with our cytokeratin-18 measurements and provide further evidence for necrosis as the 
primary mode of cell death. To assess whether or not there is an immune component, we also 
measured levels of acetylated HMGB1 and found a reverse pattern – an increase in acHMGB1 at 
the later time points. When comparing acHMGB1 to total HMGB1, there is a time-dependent 
increase in the percent of acHMGB1 from less than 5% at the peak of injury to 20-30% during the 
recovery phase (Figure 3.3.8D). Several studies point to elevated levels of pro-inflammatory 
cytokines such as IL-6 and IL-10 during the early phase of HH (Bajt et al., 2006; Wetzel et al., 
2014; Zuckerbraun et al., 2005). To determine whether the elevated acHMGB1 ratio we observed 
was an indication of a robust inflammatory response during the later stages of HH, we measured 
multiple cytokines. For most cytokines and chemokines, the highest levels were observed at the 
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Figure 3.3.8. Cell death involves DNA fragmentation and release of HMGB1. (A) Plasma levels of 
DNA fragments in HH and APAP patients from -1 to +5 days after peak injury. (B) Dot histogram 
comparing plasma levels of DNA fragments between HH patients and HV or patients with APAP 
toxicity at the time of peak injury. (C) Total HMGB1 in HH patients measured from -1 day to +5 days 
after peak injury. (D) Percent of hyperacetylated HMGB1 of total HMGB1 in the plasma of HH patients 
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Figure 3.3.9 Plasma levels of inflammatory mediators during hypoxic hepatitis. Plasma levels of 
(A) IL-4 and IL-6, (B) IL-8 and IL-10, (C) IL-1β and IL-1Ra, and (D) TNF-α and MCP-1 in hypoxic 
hepatitis patients from day 0 (peak of ALT)  to 3 days after peak of injury (line graphs) are compared 
to control levels of the same cytokines (healthy volunteers, single plots). Data represent average ± SE 
(n = 5-11 patients per time point). * = p<0.05 vs. control.  
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In order to highlight the strong correlation between each of these plasma parameters with ALT, 
the time course of ALT vs miR-122, full-length cytokeratin-18, caspase-cleaved cytokeratin-18, 
mtDNA, nuclear DNA fragments, and total HMGB1 is shown in the Figure 3.3.10 and 3.3.11. All 
parameters show a similar time-dependent increase and subsequent decrease in plasma as ALT 
(Figure 3.3.10 & 3.3.11). This is further supported by linear regression analysis, which 
demonstrated a significant correlation of each parameter with ALT on each day (Figures 3.3.6 & 
3.3.7). The only exception is plasma levels of acetylated HMGB1, an indicator of inflammatory 
cell activation, which shows neither a temporary correlation (Figure 3.3.11) nor a significance with 
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Figure 3.3.10 Relationship between ALT and plasma biomarkers. Side by side comparison 
demonstrating relationship between ALT and (A) miR-122, (B) FL-K18, (C) cc-K18, and (D) GDH 
Data is presented as the average value from the day before, to 5 days after, peak injury as measured by 





Days From Peak ALT





































Days From Peak ALT







































Days From Peak ALT



































Days From Peak ALT

















































Figure 3.3.11 Relationship between ALT and plasma biomarkers. Side by side comparison 
demonstrating relationship between ALT and (A) CytC, (B) Nuclear DNA fragments, (C) Total 
HMGB1, and (D) Acetylated HMGB1. Data is presented as the average value from the day before, to 




In the present study, we set out to investigate the mechanisms of injury during HH in patients. To 
accomplish this, we investigated a series of circulating plasma biomarkers which characterize 
mode and mechanisms of cell death in experimental models and other human liver diseases 
(Antoine et al., 2012; McGill et al., 2012; Starkey Lewis et al., 2011; Woolbright et al., 2015; 
Yang et al., 2014). Because APAP hepatotoxicity is well-characterized in both animal models and 
humans (Jaeschke, 2015), we compared the findings in patients with HH to those in patients with 
APAP toxicity.  
 
Liver injury during HH. We found liver injury in our patients fits the clinical profile of HH, mostly 
characterized by a sharp rise in ALT greater than 20 times normal. Although not liver specific, 
ALT is clinically used for assessment of liver injury. Multiple studies show that miRNA-122 is a 
more sensitive and specific indicator of ongoing liver injury, rising earlier and to a much greater 
degree than ALT (Roderburg et al., 2015; Starkey Lewis et al., 2011; Wang et al., 2009b). Because 
we detected a dramatic increase of the liver-specific miRNA-122 in HH patients similar to that 
previously observed in APAP hepatotoxicity, we conclude that the majority of ALT release in 
these patients was derived from hepatocytes – an important distinction in the setting of HH, since 
hypoxia is not limited to the liver. Our results are consistent with previously reported values of 
miRNA-122 in a porcine model of cardiogenic shock (Andersson et al., 2012). Interestingly, our 
cohort of HH patients had low plasma levels of adducts (Figure 3.3.2), however such low levels 
of adducts are well under the level which would be expected if APAP caused a significant amount 
of liver injury (James et al., 2009). More likely, these individuals consumed a therapeutic dose of 
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APAP and adducts were passively released as a result of the hypoxic event leading to HH (McGill 
et al., 2013).  
 
Mode of cell death during HH. To differentiate whether or not hepatocellular injury was occurring 
as a result of apoptosis or necrosis, we measured plasma levels of cytokeratin-18, an intermediate 
filament protein which composes part of the cytoskeleton. During apoptosis, active caspases cleave 
cytokeratin creating a neo-epitope which can be recognized by the M30 antibody. In contrast, 
during necrosis, caspases are not active and mainly full-length cytokeratin-18 is released. Thus, 
the ratio of cleaved/full-length cytokeratin-18 can be used to determine whether cells undergo 
apoptosis or necrosis. Given that at any time during the observation period >95% of the detectable 
cytokeratin-18 levels in blood of these patients was the full-length form, our data strongly suggest 
that necrosis was the dominant form of liver cell death during HH. Even still, we saw significant 
elevations in the caspase-cleaved form of cytokeratin-18 at various time points. However, no 
detectable caspase activity could be found in plasma of HH patients despite the fact that plasma 
caspase-3 activities are readily measurable in experimental models of apoptosis (McGill et al., 
2012). In light of elevated levels of caspase-cleaved cytokeratin-18, however, these results should 
be interpreted with caution, since little is known about the stability or half-life of active caspases 
in plasma. It is possible that caspases are rapidly degraded or eliminated from plasma before blood 
samples are obtained. Therefore, caspase-3 activities, especially at later time points during the 
recovery phase could be lower than in the liver. Regardless, when compared quantitatively with 
the full-length form of cytokeratin-18 (Figure 3.3.3C), it becomes clear that the vast majority of 
injury is caused by necrosis, and that apoptosis, as indicated by cleaved cytokeratin-18, contributes 
relatively little to liver injury in this setting. 
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Mitochondrial damage as a hallmark of cell death in HH. In other causes of liver injury, such as 
APAP toxicity, in which necrosis is the predominant form of cell death, mitochondria play a major 
role in the pathophysiology of injury (Jaeschke et al., 2012a). In the experimental model and in 
APAP overdose patients, mitochondrial rupture leads to release of matrix macromolecules which 
can be measured in plasma (McGill et al., 2012). Furthermore, endonuclease-G released from 
damaged mitochondria translocates to the nucleus where it causes DNA fragmentation and cell 
death (Bajt et al., 2006; Jaeschke et al., 2012a). Our results show that the increase in mitochondrial 
injury as measured by GDH and mitochondrial DNA mirror the pattern of injury as measured by 
ALT. Similarly, levels of nuclear DNA fragments follow this trend. These results provide strong 
evidence for mitochondrial damage as a key event in the mechanism of liver cell death in HH 
patients. Interestingly, our in vivo results in humans correlate with many experimental studies 
which demonstrate a critical role of mitochondria in reperfusion injury (Lemasters et al., 1997; 
Powell et al., 2014; Vairetti et al., 2006). It has been shown that during hypoxia, intracellular pH 
decreases which actually exerts a protective effect against hypoxic injury (Qian et al., 1997). 
However, upon re-oxygenation, intracellular pH returns to normal, precipitating formation of the 
MPTP and mitochondrial rupture (Qian et al., 1997; Schwartz et al., 2013). Mechanisms behind 
pH-induced mitochondrial injury are thought to involve mitochondrial calcium uptake (Schwartz 
et al., 2013). Collectively, a clinical picture begins to emerge: during a period of hypoxia, ATP 
levels fall leading to a decreased ability to sequester calcium within mitochondria (Gasbarrini et 
al., 1992; Lemasters et al., 1987). Return of oxygen allows for oxidative phosphorylation and 
elevated cytosolic calcium levels, leading to mitochondrial calcium sequestration. This incites 
formation of the MPTP, which triggers matrix swelling, rupture and necrotic cell death. Based on 
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our previous data, it is possible that endonuclease-G released from ruptured mitochondrial 
produces DNA fragmentation, but further studies are needed for verification.  
 
Role of inflammation in HH. Interestingly, we found an increase in acetylated HMGB1 
(acHMGB1) protein in plasma of HH patients at later time points. Since macrophages actively 
secrete acHMGB1 upon activation (Bonaldi et al., 2003), our data suggest activation of 
inflammatory cells during the recovery phase. These findings are consistent with activation of 
macrophages and other phagocytes for removal of cell debris and regeneration of the damaged 
tissue. However, the majority of cytokines were slightly elevated earlier. Since the gastrointestinal 
tract is very susceptible to microcirculatory changes during ischemic injury (Ceppa et al., 2003), 
it is possible that intestinal injury allows for bacterial translocation and macrophage activation 
before liver injury occurs. Thus, the initial inflammatory response is on the decline at the point 
when these blood samples were drawn and the increased acHMGB1 levels, reflecting a sterile 
inflammatory response, could be the result of macrophage activation in an attempt to clear debris 
rather than exacerbate injury (Jaeschke et al., 2012b). This has also been shown in APAP overdose 
patients, where neutrophil and monocyte activation and hepatic infiltration are crucial for liver 
repair and regeneration (Antoniades et al., 2012; Williams et al., 2014). This seems very likely 
given that injury is decreased at later time points despite an apparent activation of inflammatory 
cells. This is in stark contrast to models where inflammation is involved in propagation of injury, 
such as no-flow ischemia, in which sterile inflammation leads to exacerbation of injury well past 




Overall, our data demonstrated that HH, similar to APAP hepatotoxicity, is characterized by 
extensive mitochondrial damage and necrotic cell death. Although these mechanistic biomarkers 
gave novel insight into the mechanism of these disease states in humans, there was no relevant 
difference between the parameters in APAP and HH that would allow a more accurate diagnosis. 
However, our previous studies looking at the miRNA profile between these patient groups 
indicated that similar miRNAs with different levels and unique miRNAs can be detected in plasma 
of these patients suggesting that the miRNA profile may be used to differentiate between APAP 
hepatotoxicity and HH (Ward et al., 2014). Thus, plasma biomarkers are useful in both better 



















































4. COMPARISON OF FRESHLY DIFFERENTIATED AND 
CRYOPRESERVED PRE-DIFFERENTIATED HEPARG CELLS 





Drug safety, specifically hepatotoxicity, is a common cause for drug failure during clinical trials 
(Arrowsmith and Miller, 2013). The development of a reliable and convenient in vitro model to 
assess drug toxicity would help identify hepatotoxic compounds earlier during the drug discovery 
process, saving time and minimizing animal experiments. Currently, primary human hepatocytes 
(PHH) remain the gold standard for in vitro studies of hepatotoxicity; however, they are not widely 
available and are known to lose cytochrome-P450 activity following cryopreservation, limiting 
their usefulness in drug metabolism studies (Hengstler et al., 2000). A suitable alternative is the 
human cell line HepaRG (Guillouzo et al., 2007; Hewitt et al., 2007). These cells are favorable for 
drug toxicity studies because they contain a full complement of drug metabolizing enzymes, 
including cytochromes P450 (Aninat et al., 2006; Hart et al., 2010). Although HepaRG cells can 
withstand the cryopreservation process, the subsequent growth and differentiation period is 
lengthy and inconvenient for high throughput studies. Recently, pre-differentiated cryopreserved 
HepaRG (cHepaRG) cells have been developed, but no studies have directly compared these two 
preparations in a controlled drug toxicity study. 
Acetaminophen (APAP) overdose continues to be a major problem in the United States and 
accounts for the majority of acute liver failure cases on a yearly basis (Lee, 2013). At therapeutic 
doses, the bulk of APAP is glucuronidated or sulfated and excreted in the urine as inactive 
conjugates (Larson, 2007). However, a small percent of the dose is metabolically activated by 
P450-mediated conversion to the electrophile NAPQI by cytochrome-P450 mediated metabolism 
(Dahlin et al., 1984). This metabolic activation is driven predominantly by CYP2E1 (Lee et al., 
1996), although CYP3A4 (Thummel et al., 1993) and CYP1A2 (Snawder et al., 1994) have also 
been shown to contribute to NAPQI formation. Despite the formation of the highly reactive 
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compound NAPQI, APAP is safe at therapeutic doses because the metabolite is detoxified by the 
tripeptide glutathione (GSH), which exists at high concentrations within the hepatocyte cytoplasm 
(Larson, 2007). However, in cases of APAP overdose, sulfation is overwhelmed and a much higher 
percent of the dose is shunted through the P450 system, leading to depletion of GSH (Mitchell et 
al., 1973; Xie et al., 2015a) and increased levels of NAPQI (Lee et al., 1996). NAPQI covalently 
bind to proteins, particularly mitochondrial proteins (Cohen et al., 1997; McGill et al., 2012; Qiu 
et al., 1998; Tirmenstein and Nelson, 1989), leading to mitochondrial stress, membrane 
depolarization, and release of endonucleases which translocate to the nucleus leading to cell death 
(Jaeschke et al., 2003; McGill et al., 2012). Thus, APAP hepatotoxicity is dependent upon 3 major 
processes: metabolic activation, glutathione depletion, and mitochondrial injury, ultimately 
culminating in oncotic necrosis. Inhibition of any one or more of these processes prevents the liver 
injury. 
The acetaminophen model of hepatotoxicity is well characterized, relatively simple, and as 
previously stated, requires multiple intracellular events to occur before toxicity is observed. 
Therefore, APAP provides an ideal model for identifying any potential differences between freshly 




4.2 MATERIALS AND METHODS 
 
Cell culture. All HepaRG cells were obtained from Biopredic International (Rennes, FR). All cells 
were stored in LN2 until use. HepaRG cells were grown and differentiated as previously described 
(McGill et al., 2011). cHepaRG cells were seeded according to the manufacturer’s instructions and 
were acclimated for 1 week prior to initiation of experiments. Frozen PHH were obtained from 
Biopredic International (Rennes, FR), CellzDirect (now Life Technologies) and ZenBio (Research 
Triangle Park, NC). The frozen PHH were thawed and prepared according to the manufacturer’s 
instructions. Before seeding, frozen PHH were centrifuged with 90% Percoll to purify live cells. 
Fresh PHH were acquired through the University of Kansas Liver Center from consenting donor 
patients presenting to the University of Kansas Hospital. All samples were obtained with approval 
from the Institutional Review Board. Once approved, liver tissue was processed as described in 
detail (Xie et al., 2014b). All cell lines were maintained at 37oC and 5% CO2 before and during 
experiments. 
 
Acetaminophen treatment. At the time of treatment, growth medium was removed and cells were 
washed once with 1x PBS and treated with the indicated concentrations of APAP dissolved in 
DMSO-free William’s E medium or with Williams’ E medium alone. The cells were harvested at 
the indicated time points. 
 
Biochemistry. After acetaminophen treatment, 1 ml cell medium was collected for measurement 
of enzyme (LDH or ALT) release. Cells were then washed once with PBS, scraped in cell lysis 
buffer, and frozen at -80oC until use. Once thawed, cells were sonicated and LDH concentration 
in both medium and cell lysate was measured as previously described (McGill et al., 2011). ALT 
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levels were similarly measured using a commercially available kit according to the manufacturer’s 
instructions (Pointe Scientific, Canton, MI). 
 
APAP-protein Adducts. Following acetaminophen treatment, cells were washed once with PBS, 
scraped in 10 mM sodium-acetate buffer (pH 6.5), and frozen at -80oC until use. APAP-protein 
binding was measured using high-pressure liquid chromatography with electrochemical detection 
(HPLC-ECD) as previously described (McGill et al., 2013). The results were normalized to total 
protein concentration in cell lysates as determined by the BCA assay.  
 
GSH Depletion. GSH was measured as previously described (Jaeschke and Mitchell, 1990). 
Results were normalized to total protein concentration of cell lysate as determined by the BCA 
assay.  
 
JC-1 Assay. Mitochondrial membrane permeability was measured with the use of a commercially 
available JC-1 Mitochondrial Membrane Permeability Kit (Cell Technology, Fremont, CA) as 
described (Bajt et al., 2004).  
 
DNA isolation and qPCR. Cells subjected to P450 mRNA analysis were scraped and stored in Tri® 
Reagent (Sigma Chemical, St. Louis, MO) at -80oC until use. After thawing, mRNA was isolated 
using a standard protocol and converted to cDNA. cDNA was subject to qPCR reaction using the 
following primers: CYP2E1 (fwd: TTGAAGCCTCTCGTTGACCC, rev: 
CGTGGTGGGATACAGCCAA), CYP3A4 (fwd: CTTCATCCAATGGACTGCATAAAT, rev: 
TCCCAAGTATAACACTCTACACAGACAA), and 1A2 (fwd: 
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TGGAGACCTTCCGACACTCCT, rev: CGTTGTGTCCCTTGTTGTGC) and normalized to β-
actin (fwd: CATGTACGTTGCTATCCAGGC rev: CTCCTTAATGTCACGCACGAT). 
 
Statistics. All data are expressed as average ± SEM. Statistical significance was assessed using 
Student’s t-test or one-way analysis of variance (ANOVA) with Tukey’s post-hoc test where 







We first compared cell death in four different cell preparations: fresh PHH, frozen PHH, HepaRG 
cells, and cHepaRG cells. ALT release was measured in PHH cultures, while LDH was chosen for 
HepaRG cultures due to lower expression of ALT in this cell line. Following 24 hour treatment 
with 20 mM APAP, cell death was observed in fresh PHH, HepaRG, and cHepaRG cells (enzyme 
release: 64±6%, 23±2% and 50±10%, respectively) (Figures 4.3.1A, C, D). Notably, viability in 
cryopreserved PHH cultures was poor as indicated by excessive cell death in control samples 
(36±10%), which actually decreased after 24 hrs of APAP treatment (27±5%) (Figures 4.3.1B and 
4.3.2). Importantly, cell death between cHepaRG and fresh PHH was similar (64±6% vs. 50±10%). 
These data suggest that frozen PHH cultures are generally a poor model for drug toxicity studies, 
while fresh PHH, HepaRG and cHepaRG cells are useful. 
Because no direct comparison of HepaRG and cHepaRG cells has been performed, we wanted to 
determine whether or not these cells respond similarly to APAP. We began by measuring full time 
courses of enzyme release after APAP treatment. We found that APAP caused a time dependent 
increase in cell death in both HepaRG and cHepaRG cells, however, injury occurred faster, and 
was more severe, in cHepaRG cells compared to HepaRG cells (16hr vs. 24hr and 50±10% vs. 
23±2%, respectively) (Figures 4.3.3A, B). We then performed dose-response studies in both cell 
types. Interestingly, in HepaRG cells, there was a significant increase in cell death at 10 mM APAP 
but no additional cell death was observed with 20mM APAP (Figure 4.3.3C), despite a clear dose-
response in cHepaRG cells (Figure 4.3.3D). In addition, the degree of injury in cHepaRG cells at 
10mM was similar to that in HepaRG cells (28±15% vs. 32±4%). These results are similar to those 
observed in Figure 4.3.1C (28±1% vs. 23±2%), but differ from what we have previously reported 




















































































































Figure 4.3.1. Comparison of cell death between primary human hepatocytes and HepaRG cells. 
Release of ALT or LDH was measured in (A) fresh and (B) frozen primary human hepatocytes (PHH) as 
well as in (C) freshly differentiated (HepaRG) or (D) pre-differentiated cryopreserved (cHepaRG) 
HepaRG cells following treatment with vehicle or 20mM acetaminophen. Data are expressed as average 



























Figure 4.3.2. Microscopic comparison of primary human hepatocytes and HepaRG cells. Phase 
contrast images (400X) of (A) fresh primary human hepatocytes; (B) cryopreserved primary human 
hepatocytes; and (C) Undifferentiated cryopreserved HepaRG cells 24 hours after seeding.  









































































































Figure 4.3.3. Comparison of time-course and dose-response of cell death between HepaRG and 
cHepaRG cells. Release of LDH was measured in (A) freshly differentiated (HepaRG) or (B) pre-
differentiated cryopreserved (cHepaRG) HepaRG cells following treatment with vehicle or 20mM 
acetaminophen. Dose response curves following 24hr treatment with vehicle or various concentrations of 
acetaminophen in (C) freshly differentiated (HepaRG) or (D) pre-differentiated cryopreserved (cHepaRG) 
HepaRG cells. Data are expressed as average ± SE for 3 independent experiments. * = p<0.05 vs. control.  
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Metabolic activation of APAP leads to NAPQI formation which is detoxified by GSH, leading to 
decreased GSH levels. Therefore, depletion of GSH can be used as a measurement of metabolism 
of APAP into its toxic metabolite. To compare the ability of HepaRG and cHepaRG to form this 
reactive intermediate, we treated cells with 20 mM APAP for multiple time points up to 24 hours 
and measured GSH. Although HepaRG cells were observed to have higher basal levels of GSH 
(98±11 vs. 62±5 nmol/mg protein), we found a similar pattern of GSH depletion with an initial 
rapid decrease between 0 and 3 hr which then plateaued (Figures 4.3.4A, B). The dose-response 
of GSH depletion was also similar, resulting in approximately 34% and 37% depletion of GSH in 
HepaRG and cHepaRG, respectively, after 10 mM APAP, and 68% and 70% depletion of GSH in 
HepaRG and cHepaRG, respectively, following 20mM APAP (Figures 4.3.4C, D).  
If NAPQI is not detoxified by GSH, it can covalently bind to sulfhydryl groups on cysteine 
residues to form APAP-protein adducts. To further test formation of NAPQI in the cells, we 
measured the levels of protein-derived APAP-cys and found that although maximum adduct 
formation was higher in cHepaRG cells compared to HepaRG cells (0.44±0.05 vs. 0.28±0.04 
nmol/mg protein, respectively) (Figures 4.3.5A, B), the time course was similar between the two 
preparations. Both HepaRG and cHepaRG cells demonstrated a sharp rise in adduct formation 
between 0 and 6 hrs post-APAP treatment, followed by a gradual decline to 24 hrs.  
We also compared the levels of P450 mRNA between HepaRG and cHepaRG for those P450s 
known to play a role in APAP metabolism. Interestingly, we observed a trend toward higher 
CYP2E1 and CYP3A4 mRNA levels in cHepaRG cells which may explain the higher APAP-
protein adduct concentrations in these cells. We also found a slight decrease in CYP1A2 mRNA 






















































































































Figure 4.3.4. GSH Depletion is similar between ‘Regular’ and cryopreserved HepaRG cells. Time 
course of GSH depletion following acetaminophen treatment (20mM) in (A) freshly differentiated 
(HepaRG) and (B) pre-differentiated cryopreserved (cHepaRG) HepaRG cells. Dose-response of GSH 
depletion following acetaminophen treatment in (C) freshly differentiated (HepaRG) and (D) pre-
differentiated cryopreserved (cHepaRG) HepaRG cells at 24 h. Data are expressed as average ± SE for 3 

































































Figure 4.3.5. Time course of APAP-protein adducts in HepaRG cells. Acetaminophen-cysteine 
protein adducts were measured in (A) freshly differentiated (HepaRG) and (B) pre-differentiated 
cryopreserved (cHepaRG) HepaRG cells following treatment with 20mM acetaminophen for various 
times. Data are expressed as mean±SE for 3 independent experiments. * = p<0.05 vs. control. 
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significant (Table 4.3.1). Taken together, our results suggest similar phase I drug metabolism 
capabilities in HepaRG and cHepaRG cells. 
Mitochondrial damage and membrane permeability plays a key role in APAP toxicity. With this 
in mind, we set out to determine the extent to which mitochondrial membrane permeability plays 
a role in the cell death measured in Figure 4.3.1. We performed the JC1 assay to assess 
mitochondrial membrane potential after APAP treatment in both HepaRG and cHepaRG cells. 
Again, we found that the two cell preparations showed a similar response to APAP treatment. After 
3 hrs, mitochondrial membrane potential decreased 32±1% in HepaRG cells compared to 32±5% 
in cHepaRG cells (Figures 4.3.6A, B). Furthermore, mitochondrial membrane potential remained 
low relative to control in both HepaRG and cHepaRG cells over 24 hrs. These data suggest that 
downstream events occurring during APAP toxicity are similar between the two cell preparations. 









Table 4.3.1 CYP Activity Level 
Table 4.3.1. Comparison of mRNA levels of major cytochrome P450 enzymes involved in APAP 
metabolism between cryopreserved predifferentiated HepaRG cells and undifferentiated 






































































Figure 4.3.6. Time course of mitochondrial permeability in HepaRG cells. Red/green ratio from JC-
1 assay (normalized to control) in (A) freshly differentiated (HepaRG) and (B) pre-differentiated 
cryopreserved (cHepaRG) HepaRG cells following treatment with 20mM acetaminophen. Each time 





In the present study, HepaRG and cHepaRG cells were compared for their ability to metabolize 
APAP and develop subsequent toxicity. To this end, we focused on several aspects of APAP 
metabolism and toxicity: GSH depletion, adduct formation, and mitochondrial membrane 
permeability, all events shown to be critical for APAP toxicity (Jaeschke et al., 2012a; McGill et 
al., 2011). We found that although there were quantitative differences between the two cell 
preparations, the overall pattern of injury in cHepaRG cells were similar to HepaRG in all 
measured parameters.  
Due to inter-species differences, primary human hepatocytes are the gold standard for in vitro drug 
toxicity studies. However, limited availability of these cells hinder their usefulness for most labs. 
The development of a long-term maintenance medium for PHH (Runge et al., 2000) has helped 
with viability of PHH in culture for longer periods of time, however CYP mRNA decreases within 
24hrs (Rodríguez-Antona et al., 2002), preventing the use of PHH in prolonged studies of drug 
metabolism. Additionally, as we have demonstrated, the viability of frozen PHH following 
cryopreservation is poor (Figure 4.3.2E), necessitating their immediate use following procurement. 
Thus, the ability to perform rapid high-throughput drug screening with PHH remains difficult. 
The human hepatoma cell line HepaRG has been shown to be a comparable alternative to primary 
human hepatocytes for studies of drug metabolism (McGill et al., 2011). This cell line is superior 
to frozen human hepatocytes for several reasons. First, unlike primary human hepatocytes which 
are only sporadically available, HepaRG cells are commercially available. Second, HepaRG cells 
have the same level of drug metabolizing enzymes and transporters as primary human hepatocytes 
(Anthérieu et al., 2010) making them far more useful for drug metabolism studies than other liver 
cell lines such as HepG2, which do not retain CYP levels (Aninat et al., 2006). Third, functional 
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CYP levels in HepaRG cells remain stable over prolonged periods allowing for the possibility of 
long term drug toxicity studies (Jossé et al., 2008). Finally, HepaRG have little phenotypic 
variation (Lambert et al., 2009) minimizing variation between experiments. Despite these 
advantages, the major disadvantage to the use of these cells is a lengthy and inconvenient growth 
and differentiation period required prior to the initiation of experiments. Thus, pre-differentiated 
cryopreserved (cHepaRG) HepaRG cells represent a convenient alternative. 
Interestingly, we found that cHepaRG cells exhibited both decreased basal levels of GSH and 
increased CYP2E1 and CYP1A2 mRNA (Figures 4.3.5A, B and Table 4.3.1) when compared to 
HepaRG cells. These differences could explain the variation in the magnitude of cell death between 
HepaRG and cHepaRG cells observed in the current study (Figure 4.3.1). Although the differences 
in CYPmRNA were not statistically significant, the 12-fold increase in CYP2E1, the major CYP 
responsible for APAP activation (Manyike et al., 2000), could explain the difference in adduct 
formation between the two preparations. With less GSH to detoxify NAPQI, levels of the reactive 
intermediate would be expected to increase, leading to greater adduct formation and increased cell 
death. This seems likely given the fact that fewer adducts were measured during all time points in 
HepaRG cells compared to cHepaRG cells. Nevertheless, the basis for decreased basal levels of 
GSH and increased CYP mRNA levels in cHepaRG cells requires further investigation.  
Other in vitro models for the study of drug toxicity are lacking in either convenience, availability, 
or functional stability. First among these are the use of various immortalized cell lines, such as 
HepG2. While the HepG2 line may be useful for certain in vitro studies of liver function, their lack 
of CYP enzymes makes them a poor choice for drug metabolism studies (Hewitt and Hewitt, 
2004). Other cell lines maintain high CYP levels, such as Huh7, however poor stability at high 
confluence in culture prevents their use for long term drug metabolism studies (Guguen-Guillouzo 
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and Guillouzo, 2010). Fresh precision cut liver slices have also been used. While the major 
advantage is the retention of the 3D liver architecture, both viability and enzyme level rapidly 
decrease following acquisition, as with primary human hepatocytes (Guguen-Guillouzo and 
Guillouzo, 2010). Finally, 3D models (spheroids) have been developed which preserve structure 
and function of hepatocytes as well as CYP levels (Xia et al., 2012). However, during prolonged 
culture of spheroids, extreme care must be taken to maintain spheroid size to optimize results. 
Failure to do so would likely lead to differential oxygen or drug delivery to spheroids of various 
sizes (Xia et al., 2012) which would be expected to influence the results. Despite multiple in vitro 
methods for study of the liver, HepaRG remains the only model which both recapitulates PHH 
drug metabolism and possesses the necessary stability in culture for long term studies. The 
development of pre-differentiated cryopreserved HepaRG (cHepaRG) cells which are functionally 
similar to undifferentiated cryopreserved (HepaRG) cells eliminates the need for lengthy growth 
and differentiation required of HepaRG cells. 
In summary, we have compared, for the first time, APAP metabolism between freshly 
differentiated HepaRG cells (HepaRG) and pre-differentiated cryopreserved HepaRG cells 
(cHepaRG). We found that although there were slight differences in the overall magnitude of all 
measured parameters between HepaRG and cHepaRG cells, the pattern of toxicity between the 
two preparations is remarkably similar following APAP administration. Therefore, we conclude 
that pre-differentiated cryopreserved HepaRG cells represent a suitable and convenient alternative 








5.1 SUMMARY  
In a series of studies, we employed non-invasive methods for the description of the molecular 
events leading up to cell death following liver injury from ischemic injury. We explored both cold 
and warm ischemic injury in the context of OLT and hypoxic hepatitis, respectively. To do this, 
we used a previously established set of biomarkers which are useful in differentiating between 
apoptosis and necrosis, determining the role of mitochondria in injury, and identifying a role of 
the immune system in injury. Additionally, we demonstrated that there was no significant 
difference in acetaminophen metabolism between two preparations of HepaRG cells, paving the 
way for the widespread use of the pre-differentiated cryopreserved HepaRG cells in studies of drug 
toxicity. This finding will allow for the rapid screening for the potential of hepatotoxicity of 
numerous drugs and aid in identification of drugs which may cause idiosyncratic drug induced 
liver injury.  
 
5.2 NOVELTY OF THE USE OF BIOMARKERS TO STUDY ISCHEMIC LIVER INJURY 
 
Our findings demonstrate that the use of biomarkers of injury, mode and mechanism of cell death, 
and inflammation, are not only novel for the study of ischemic injury in humans, but also 
underscore the discrepancy between certain animal models and the ability of these models to 
recapitulate the human condition. For instance, following warm ischemia in the rodent, there is a 
marked immune response which leads to exacerbation of injury. In contrast, during warm ischemia 
in humans, such a response does not occur. One detail of these studies which sets it apart from 
other studies using biomarkers is that we collected samples for an extended time frame, rather than 
studying a single time point, or a short time course shortly after the ischemic event. The importance 
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of this can be underscored by comparing our findings to previously published data from the mouse 
model of ischemic injury. In this model, there are two phases of injury – the early stage, in which 
ischemic injury leads to cell death, and the late stage, in which cellular debris (DAMPs) released 
from necrotic cells in the early stage leads to activation of macrophages, recruitment of neutrophils, 
and subsequent injury. In studies which only examine a short time course following ischemia, the 
late phase, during which inflammation plays a major role may be overlooked. Thus, these 
biomarkers represent a convenient way to obtain detailed information into the events leading to 
liver injury well after the initial injurious event. The fact that the injury pattern in the later stages 
of ischemia in humans did not have a similar pattern seen in the mouse model of ischemia, 
demonstrates the critical importance of prolonged monitoring and highlights the importance of 
selecting appropriate animal models when studying human conditions. In the case of the rodent 
model of ischemia, the ischemic time is titrated in order to study mechanisms of injury. A major 
drawback to using the rodent model of ischemia is that due to surgical advances, the level of injury 
observed is not well represented by a mouse model based on prolonged ischemic times. Future 
studies using the rodent model of ischemic injury as a surrogate for human liver transplantation 
should be designed and interpreted with this in mind.  
 
5.3 APOPTOSIS VS. NECROSIS IN ISCHEMIC LIVER INJURY 
 
Quite possibly one of the biggest ongoing disputes within the study of ischemic liver injury is 
whether cells die via apoptosis or necrosis. While this may seem like an academic argument, there 
exists a great deal of clinical significance; targeting the appropriate mode of cell death could be 
expected to minimize the progression of injury following ischemic insult in man. While some 
literature suggests apoptosis is the primary form of injury following ischemia (Compagnon et al., 
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2017; Freitas et al., 2017; Ko et al., 2017), we have demonstrated that following warm ischemia, 
necrosis appears to be the predominant form of cell death (Weemhoff et al., 2017; Yang et al., 
2014). Likewise, unpublished results from our laboratory demonstrate the same is true with cold 
ischemia following liver transplantation. While biopsy with histopathologic analysis would be 
needed to confirm necrosis following OLT and HH, our laboratory has shown previously, that 
following an episode of warm ischemia, >99% of cells die by necrosis. (Yang et al., 2014). One 
problem with many studies claiming that apoptosis is the primary mode of cell death is the use of 
only a single time point or inappropriate conclusions drawn from the use of the TUNEL assay. 
Even cytokeratin biomarker data can be misinterpreted if not presented or interpreted properly. 
For instance, one study demonstrates that following ischemic injury there is an increase in caspase-
cleaved keratin-18 at 6hrs post reperfusion. However, data for full length keratin-18, or additional 
time points, are not shown. Indeed, even in our studies, we have shown that in both types of 
ischemic injury, caspase cleaved keratin can be elevated during reperfusion relative to healthy 
volunteers, and can even be elevated relative to other time points. However, when taken in context 
of the entire time course of injury, and in relationship to full length keratin, it becomes obvious 
that necrosis is the predominant mode of cell death. Similarly, many studies rely only on TUNEL 
staining to conclude that apoptosis is the primary form of cell death. However, it is well known 
that the TUNEL assay is not specific for apoptotic cell death (Grasl-Kraupp et al., 1995). Thus, 
data obtained from the TUNEL assay should be interpreted with caution.  
Although both necrotic and apoptotic cells are identified using the TUNEL assay, we have 
previously shown that the pattern of TUNEL staining can be used to help differentiate between the 
two forms of cell death (Yang et al., 2014). As discussed previously, apoptotic cells will typically 
appear as small, condensed cells, either individually or in clusters, due to the apoptotic process. In 
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contrast, necrotic cells typically appear as large diffuse areas of staining due to membrane rupture 
and release of stain into the surrounding area. Because of the propensity for misinterpretation of 
the TUNEL assay, researchers intending to differentiate between the two forms of cell death in the 
absence of histopathology should use a secondary method in conjunction with the TUNEL assay. 
Such methods include, but are not limited to, caspase activity assays, Western blotting for cleaved 
caspase-3, and interventional studies using caspase inhibitors and/or necrostatins when possible. 
Even still, studies can be misinterpreted; a study claiming that apoptosis predominates after OLT 
was based on the fact that caspase inhibitors added to the preservative offered some protection 
against cell death. However, this study did not take into the account that the caspase inhibitors 
were added to the preservative at a concentration high enough to non-specifically inhibit proteases 
which may be responsible for necrotic cell death (Schotte et al., 1999). 
 
5.4 MITOCHONDRIAL INVOLVEMENT IN ISCHEMIC LIVER INJURY 
 
In addition to the differentiation between apoptosis and necrosis, we also demonstrated that 
mitochondria play a role cell death following ischemic injury. This finding confirms earlier cell 
culture data in which treatment of hepatocytes with mitochondrial protectants minimized injury 
following ischemia. In our studies, we measured GDH and mitochondrial DNA to identify 
mitochondrial injury and found a rise in GDH which mimicked that of ALT. The rise in GDH is 
significant because it implicates the mitochondria as an important component of cell death. An 
argument against this could be that the assay is measuring GDH from intact mitochondria released 
into circulation following cell death, implying that cell death occurs independently of 
mitochondrial injury. However, in our studies, plasma samples were centrifuged to remove intact 
mitochondria prior to the measurement of GDH. In addition, it has been shown that cell death can 
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occur in the absence of mitochondrial injury (McGill et al., 2012). Based on these findings, future 
research should explore the exact role mitochondrial injury plays in the pathophysiology of 
ischemic injury in patients. Currently, mitochondrial targeted therapies (such as Mito-tempo) are 
being developed to protect against drug induced liver injury (Du et al., 2017). The use of these 
agents could also be explored in the context of ischemic liver injury for potential use in the clinic 
in these patients.  
 
5.5 INFLAMMATION FOLLOWING ISCHEMIC LIVER INJURY IN HUMANS 
 
Based on our data, we conclude that inflammation does not play a major role in liver injury 
following transplantation or hypoxic hepatitis. This is in stark contrast to conclusions made about 
liver transplantation based on the mouse model. The most likely explanation for the discrepancy 
between the injury pattern between the two models is the preservation period during the ischemic 
period in OLT. Factors such as preservation techniques, optimal surgical strategy, and appropriate 
donor-recipient matching all help minimize the degree of injury which occurs during the ischemic 
period. As we know from the rodent model, it is the initial injury and release of DAMPs which 
leads to macrophage activation, the recruitment of neutrophils, and additional injury (van Golen 
et al., 2012; Jaeschke et al., 1990, 1992). Therefore, it stands to reason that with very little injury 
to begin with, there would be little to no response by the immune system. Indeed, data from both 
studies suggest that inflammation plays little to no role in the development of injury in our patients. 
For liver transplantation, the combination of preservatives and limited cold ischemia time could 
explain the lack of injury (and subsequent inflammation). However, during hypoxic hepatitis (HH), 
the lack of inflammation can less easily be explained, as this condition experiences warm ischemia 
for prolonged periods of time, similar to the rodent model. Nevertheless, based on the pattern of 
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liver injury observed in these patients, inflammation does not appear to exacerbate liver injury. 
Likewise, with liver transplantation, we would expect an increase in ALT at times well after 
reperfusion if inflammation played a key role in the late stages of injury. Furthermore, this rise in 
ALT would likely correlate with activation of the immune systems, as in the rodent model. 
However, following liver transplantation, we did not observe a change in neutrophil activation 
suggestive of an immune component of injury. Instead, we observed an increase in ALT only 
shortly after ischemia with a gradual decline to baseline levels over time. Because neutrophil-
depleting antibodies are protective against ischemic injury in mice (Jaeschke et al., 1990), the lack 
of neutrophil activation in our patients strongly suggests the lack of an inflammatory component. 
However, the direct measurement of pro- and anti-inflammatory cytokines would be necessary for 
a more direct and conclusive assessment of the immune response following liver transplantation. 
Even still, neutrophil and cytokine data would need to be interpreted in conjunction with liver 
injury, as neutrophil infiltration occurs in other models of liver injury, namely acetaminophen 
toxicity, without causing additional injury (Williams et al., 2014). In this model, neutrophil 
infiltration is thought to be beneficial for initiation of the regenerative response (Williams et al., 
2014).   
 
Not surprisingly, the degree of injury in HH patients was significantly higher than in OLT patients. 
In our study however, survival following HH was higher than reported in the literature (93% vs. 
50%) (Fuhrmann et al., 2010; Hawker, 1991). While there exist several possible explanations for 
this discrepancy, the most likely is that in our study, patients were mostly healthy individuals with 
a single documented episode of hypotension, often induced by an opioid overdose. In contrast, 
numbers reported in literature often reflect elderly patients with significant health issues including 
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cardiac or respiratory disease (Fuhrmann et al., 2009). Other reasons for the discrepancy could 
involve other co-morbidities not identified or accounted for in our study. Another likely cause for 
the discrepancy in survival rate amongst hypoxic hepatitis patients is simply the sample size of our 
study, which included only 13 patients. The incorporation of more patients into our hypoxic 
hepatitis study would be beneficial for the advancement of our knowledge of this field and allow 
us to subdivide patients based on co-morbidities and underlying cause of the initial ischemic insult. 
Furthermore, a larger patient population would possibly allow us to use this biomarker data to aide 
in prognosis of these patients. One major obstacle for the addition of additional patients to this 
study is that a diagnosis of HH is made only after ruling out other causes of liver injury (namely 
DILI). Therefore, any patient whose clinical symptoms match those of hypoxic hepatitis would 
need to be enrolled in a study prior to a diagnosis of HH. This alone does not present much of a 
challenge, but multiple blood collections would need to be obtained while a diagnosis is pending. 
Furthermore, markers of neutrophil activation, such as CD11b expression, ROS production, and 
phagocytic activity need to be measured within hours of blood collection. While none of these are 
insurmountable obstacles, an ongoing study of HH would need to account and plan for the 
consumption of added time and expenses for patients who, in the end, may not even be diagnosed 
with HH.  
 
Due to the discrepancies between the rodent model of ischemia and the pattern of injury following 
cold and warm ischemia studied in this dissertation, it is at least clear that the rodent IR models as 
they are currently used are not appropriate for translation to OLT patients. Furthermore, based on 
the degree of injury in our HH patients, it is equally clear that the HH model in rodents, mainly 
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hemorrhagic shock/resuscitation, needs to be refined to be more consistent and representative of 
the degree of injury in humans.  
 
5.6 COMPLICATIONS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION 
 
A major conceptual difference between the mouse model of ischemia and extrapolation to human 
transplantation is that the mouse model focuses on degree of injury as an end-point. In human liver 
transplantation, every effort is made to minimize injury, but the degree of injury as measured by 
ALT is not the end-point. In fact, the degree of injury following surgery provides the physician 
very little information as to the success or likely outcome of the procedure. This is exemplified by 
the fact that graft rejection following transplantation is seldom due to acute hepatocellular injury, 
but rather due to complications arising from the biliary system (Seehofer et al., 2013; Song et al., 
2014; Wojcicki et al., 2008). The most common cause of complications from OLT today are, in 
fact, biliary strictures (Karimian et al., 2014). Unpublished data from our study show that about 
20% percent of patients developed biliary stricture and this is in line with previously published 
reports (Giacomoni et al., 2006; Kochhar et al., 2013; Soejima et al., 2006). However, we did not 
find any correlation between the development of stricture and graft failure, or survival. 
Furthermore, of major importance is that the majority of these strictures were extrahepatic, rather 
than intrahepatic biliary stricture. One common cause for these types of strictures are typically due 
to surgical technique or donor matching (biliary ductal size mismatch) (Karimian et al., 2014; 
Verdonk et al., 2006). In our study, most patients received biliary stents at the time of 
transplantation, minimizing or eliminating the risk of stricture formation. Of more concern, are 
intrahepatic biliary strictures, which are thought to be caused due to ischemic injury of the biliary 
epithelial cells (Buis et al., 2006; Sanchez-Urdazpal et al., 1992). Indeed, it has been shown that 
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biliary epithelial cells are more susceptible to ischemia than hepatocytes (Imamura et al., 1997; 
McKeown et al., 1988; Noack et al., 1993) and this leads to areas of stenosis within the biliary 
tree, leading to chronic injury and complications. Intrahepatic biliary strictures seem to be more a 
result of warm ischemic-time than cold ischemic time because when they occur, they generally 
occur in patients who received a liver from a donor after cardiac death (Pine et al., 2009). During 
organ harvest, the liver can be harvested following declaration of brain death or cardiac death. 
During brain death, the liver may still be receiving adequate blood flow from the heart up until the 
time of removal. Thus, there is minimal warm ischemia. Conversely, the organ may be harvested 
following cardiac death, which can be a prolonged process involving hypotension, hypoperfusion, 
and prolonged warm ischemic injury well before the organ is harvested. In our study, it is unknown 
as to which patients received a liver from a donor following brain or cardiac death, but the low 
incidence of non-anastomotic biliary strictures suggests that most xenografts were obtained 
following brain death. Though it is generally accepted that non-anastomotic biliary strictures are 
primarily a function of warm ischemia, (Abt et al., 2003; Cursio and Gugenheim, 2012; Pine et al., 
2009; Taner et al., 2012; de Vera et al., 2009) they are not a commonly reported complication of 
hypoxic hepatitis. This is an interesting observation because during hypoxic hepatitis, the liver 
undergoes prolonged warm ischemic times and thus these strictures would be expected to occur in 
high frequency in these patients. One explanation for this discrepancy could simply be that due to 
the high mortality rate with hypoxic hepatitis, many patients do not survive long enough to develop 
biliary stricture. Alternatively, the pathophysiology of biliary stricture could be multifactorial and 
involve more than ischemic injury to biliary epithelial cells. Thus, long term monitoring of patients 
following an episode of hypoxic hepatitis might provide valuable information into the role of warm 
ischemia on the pathophysiology of non-anastomotic strictures.  
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The fact that there were very few intrahepatic biliary stricture patients in our study is consistent 
with the overall degree of injury following liver transplantation and can also be attributed to both 
cold ischemia (vs. warm ischemia) and the use of preservatives. There have been studies 
suggesting that certain miRNAs released from biliary epithelial cells upon their death may be 
predictive for the formation of intrahepatic biliary stricture (Verhoeven et al., 2013). However, 
due to deviation from standard of patient care combined with the invasive nature of the procedure, 
the collection of bile over an extended period of time for the measurement of miRNA was not 
possible for our study and we were unable to explore this hypothesis. Thus, follow up studies for 
this purpose would provide significant information as to the pathophysiology of the development 
of biliary strictures. Regardless, our studies show that biomarkers represent a convenient and easy 
way to study both these conditions when invasive methods are unavailable or contraindicated.  
 
5.7 UNDIFFERENTIATED VS. PRE-DIFFERENTIATED CRYOPRESERVED HEPARG 
CELLS 
 
HepaRG cells have been used in the laboratory since 2002 (Gripon et al., 2002) and are useful 
compared to other cell lines for a variety of reasons. Importantly for studies of drug metabolism, 
HepaRG cells carry a full complement of active CYP enzymes while other cell lines, such as 
HepG2, do not (Aninat et al., 2006; Kanebratt and Andersson, 2008; Sassa et al., 1987). Because 
of the time-consuming nature of their growth and differentiation process, HepaRG cells are not 
always practical for short experiments in the lab. To overcome this obstacle, and promote the 
widespread use of this cell line, methods to cryopreserve differentiated HepaRG cells have been 
developed. While the growth and differentiation process remain the same, the cells are preserved 
in a differentiated state. Upon initiation of an experiment, the cells are thawed, plated, and allowed 
to grow for a short period (approximately 1 week) prior to their use in experiments. In contrast, 
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HepaRG cells purchased at passage 17 would require a minimum of 8 weeks for growth and 
differentiation. However, prior to the onset of our study, no group has directly compared the pre-
differentiated HepaRG cells to the undifferentiated cells. Our findings detailed in Chapter 4 
demonstrate that the two different preparations respond biologically similarly and thus can be used 
interchangeably. Perhaps of equal importance, we demonstrated that these cells are also 
comparable to primary human hepatocytes, the gold standard for in vitro hepatotoxicity research. 
Since primary human hepatocytes are only sporadically available, require special and lengthy 
isolation techniques, and do not tolerate the freeze/thaw cycle well, their use is often limited to 
laboratories equipped to handle their immediate isolation and use. These findings set the stage for 
the widespread use of HepaRG cells in drug toxicity studies.  
Acetaminophen toxicity is the most common cause of liver failure in the United States (Budnitz et 
al., 2011; Lee, 2013). This is due, in part to the fact that acetaminophen is readily available as an 
over-the-counter analgesic and antipyretic. In fact, according to the FDA, more than 24 billion 
doses of acetaminophen were sold in 2008 and more than 48 million people use acetaminophen on 
a regular basis. In addition to this, acetaminophen is commonly added to opioid analgesics such as 
Vicodin (hydrocodone and acetaminophen) and Percocet (oxycodone and acetaminophen). This 
strategy allows for the reduction in opioid, and its potential for habit forming behavior, without 
compromising pain relief for the patient. However, if patients are unaware that these medications 
contain acetaminophen, they are likely to self-administer additional acetaminophen for the relief 
of break-through pain. This can lead to accidental overdose. Indeed, in 2011 there were over 
80,000 cases of acetaminophen, 50% of which led to acute liver failure (Budnitz et al., 2011). 
While an antidote exists (N-acetylcysteine), this is only effective if given shortly after a toxic dose. 
Since many overdoses are either unknown or intentional, this becomes impractical in the clinical 
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setting. Thus, the study of the mechanisms of acetaminophen toxicity and interventions to 
minimize injury after the window during which NAC would be effective has tremendous 
application in the clinical setting.  
APAP hepatotoxicity is well characterized in humans and rodents; it is known to involve CYP-
mediated metabolic activation, glutathione depletion, and mitochondrial injury. Because of the 
frequency with which acetaminophen hepatotoxicity occurs, we used the acetaminophen model of 
drug induced liver injury to identify any potential differences between freshly differentiated 
HepaRG cells and cHepaRG cells. As discussed in the previous chapter, we found that the response 
to acetaminophen toxicity between both cell preparations were remarkably similar with respect to 
all facets of acetaminophen toxicity. 
However, despite the similarities, we did see a difference in CYP mRNA levels. While this 
difference was not statistically significant and did not appear to affect the overall behavior of the 
cells, cryopreserved pre-differentiated HepaRG cells had a higher expression of CYP2E1, 3A4, 
and 1A2 than their counterpart. One possible explanation for this could lie in the growth and 
differentiation process, during which approximately 50% of the total cell population become 
hepatocytes and the rest develop into biliary epithelial cells (Gripon et al., 2002; Parent et al., 
2004). This, however, is a rough estimate and each individual culture could have more of one type 
than the other. Thus, when working with HepaRG cells, CYP mRNA levels should be normalized 
to hepatocyte specific proteins, such as albumin. Nevertheless, despite the absolute expression of 
CYP enzymes, CYP activity between the two were not different. Thus, we conclude that the pattern 
of toxicity and injury is similar between the two preparations suggesting they can be used in other 
models of DILI. Since hepatotoxicity is the most common cause of drug failure and post-market 
withdrawal, the widespread use of HepaRG cells in the drug development process would likely 
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help identify drugs with the potential for hepatotoxicity before they make it to clinical trials or to 
market. By identifying these compounds earlier in the process, there exists not only a financial 
benefit to the pharmaceutical company, but more importantly, a significant decrease of risk to the 
general public.  
The overall convenience of these cells can be extrapolated to other areas of hepatology. In fact, 
our laboratory has already demonstrated that in addition to similarities in the metabolism of 
acetaminophen, HepaRG cells respond similarly to primary human hepatocytes in studies of bile 
acid toxicity, eliminating the need for the primary cell line for these studies.(Woolbright et al., 
2016) HepaRG cells could theoretically replace PHH for ischemic hepatitis studies. Furthermore, 
the use of HepaRG cells could expedite the field of biomarker research by serving as a platform 
for the identification of additional hepatocyte or biliary biomarkers of injury, or even regeneration, 
under a variety of conditions. Indeed, studies are already using these cells in biomarker research 
following drug toxicity.(Marrone et al., 2016) Finally, because HepaRG cells are a mixed 
population of hepatocytes and biliary epithelial cells, this cell line could potentially be used in 
studies of biliary epithelial cells. 
 
5.8 CONCLUDING REMARKS 
 
In summary, we have demonstrated that the use of previously identified biomarkers can be useful 
in describing the events following both warm and cold ischemic injury in humans. While our 
findings and conclusions provide significant advances to our understanding of the pathophysiology 
of ischemic injury in patients, more research is necessary to refine this knowledge. Future studies 
should be directed at determining the role of mitochondria in cell death following ischemia, 
identifying biomarkers of biliary injury and stricture, and identifying biomarkers of prognosis and 
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outcome. Based on our findings with the HepaRG cell line, the widespread use of these cells may 
help to accelerate research and discovery within the field of drug hepatoxicity and safety studies, 
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